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This thesis addresses a variety of aspects of the early diagnosis of Alzheim-
er’s disease (AD). AD is a complex clinical syndrome characterized by a 
cluster of symptoms and signs comprising difficulties in memory, changes 
in behaviour, disturbance in language and other cognitive functions caus-
ing impairments in activities of daily living. (Ferri et al., 2005; Qiu et al., 
2009; Villemagne et al., 2013). In 2010, 5,4% of the European population 
at the age of 60+ had dementia, which was (at that time) 6.3 million peo-
ple (Wittchen et al., 2011). AD accounts for 75% of all dementia cases, 
implying 4.7 million people in Europe had AD in 2010 and this number is 
further increasing. Brookmeyer et al., predicted an AD incidence of 1 in 85 
persons worldwide in 2050 (Brookmeyer et al., 2007). As a result, AD rep-
resents an important socio-economic and public health concern. Results 
from human studies suggest that females are at higher risk for developing 
AD than men (Andersen et al., 1999; Corder et al., 2004; Grimm et al., 
2012; Janicki and Schupf, 2010; Musicco, 2009)
Due to an incomplete understanding of the pathophysiology of the dis-
ease, an effective therapy is currently not available. Limitations in stud-
ying the early stages of the disease during life, have been partly respon-
sible for lack of knowledge about the pathophysiology of AD. However, 
there are promising strategies, some of which are already effective in 
animal models and some are tested in clinical trials including immuno-
therapy (Lambracht-Washington and Rosenberg, 2015; Landlinger et al., 
2015), inhibition of Aβ production (Howell et al., 2015; Wang et al., 2012) 
or tau aggregation (Harrington et al., 2015; Richter et al., 2014; Wischik 
et al., 2014; Wischik et al., 2015). The ability to detect the disease in an 
early stage would help increasing the knowledge on the pathophysiology 
of AD, would improve the chances for developing effective treatments, 
and would widen the therapeutic window for effective treatment.
However, at the moment AD is difficult to diagnose at an early stage and 
even at advanced stages of the disease a definitive diagnosis of AD still 
requires an autopsy. Therefore, diagnostic methods are needed allowing 
early in vivo detection of AD pathology (Jack, Jr. et al., 2010). 
Pathology
The main pathological hallmarks of AD are atrophy, neurofibrillary de-
generation and extracellular amyloid plaques (figure 1 and 2) (Doens and 
Fernandez, 2014; Dore et al., 2013; Ma et al., 2014; Price et al., 1991; 
Takahashi et al., 2010; Villemagne et al., 2013). All these can also be 
demonstrated in non-demented elderly subjects and therefore, are not 
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specific for AD but their quantity and distribution in relation to the clinical 
symptoms is specific (Thal et al., 2014). It has been demonstrated that 
plaques and tangles lead to synaptic dysfunction, mitochondrial damage, 
inflammation and neuronal death (Doens and Fernandez, 2014; Taka-
hashi et al., 2010). It still remains unknown how these pathological hall-
marks are related to each other. Another frequent finding in AD is cerebral 
amyloid angiopathy (CAA) that can also contribute to the cognitive decline 
(Weller et al., 2009). More recently, changes in iron distribution have been 
noted (Bartzokis, 2011; Crichton et al., 2002; Haacke et al., 2005; Mead-
owcroft et al., 2015a; Meadowcroft et al., 2015b).
Atrophy 
Shrinkage of the brain associated with AD is regarded as a valid marker 
of disease state and progression. Brain atrophy is correlated to neurofi-
brillary tangles (NFT) and neuropsychological deficits. It starts, in the 
majority of AD patients, in the hippocampus and the enthorinal cortex, 
extending to the temporal, parietal and frontal neocortices during the dis-
ease progression (Frisoni et al., 2010). 
Figure 1: Examples of neurofibrillary tangles 
(arrows), neuropil threads (arrowheads) and 
dystrophic neurites (asterix).
Neurofibrillary degeneration
Neurofibrillary tangles (NFT) are 
one of the manifestations of neu-
rofibrillary degeneration, the oth-
er being neuropil threads (NT) 
and dystrophic neurites (DN) (fig-
ure 1). In all these lesions there 
is intracellular accumulation of 
hyper-phosphorylated tau pro-
tein, forming soluble aggregates 
and paired helical filaments (PHF) 
(Kidd, 1963). NFT are neuronal 
cell bodies filled with PHF whereas 
in NT these PHF are present in the 
neuronal processes. DN are NT 
with irregular, dilated and distort-
ed shapes. Normally tau proteins 
are involved in structural and reg-
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ulatory function of the cytoskeleton where they promote the assembly of 
microtubule and their stability (Alonso et al., 2008; Grundke-Iqbal et al., 
1986). However, when tau becomes hyper phosphorylated it exerts the 
exact opposite effect, leading to the dismantling of the same microtubule. 
The resulting loss of neuronal structure impairs axonal transport, lead-
ing to disturbed proper synaptic, neuronal signalling and eventually leads 
to neuronal death (Ballatore et al., 2007). The degree of tau pathology 
correlates very well with dementia but neurofibrillary degeneration is not 
specific for AD: it is also seen in other neurodegenerative diseases, al-
though with a different distribution in the brain. 
Plaques
Plaques represent a wide array of lesions that contain extracellular de-
posits of amyloid β protein (Aβ) of which variable amounts are present as 
amyloid. Histologically, plaques are classified as diffuse,  compact, classi-
cal and neuritic plaques. The type of plaque depends on the density and 
circumscription of Aβ (diffuse vs. compact plaques), the presence of an Aβ 
amyloid core (classical plaque) and the coexistence of dystrophic neurites 
(neuritic plaque) (figure 2) (Duyckaerts et al., 2009). Aβ plaques in an 
extensive amount is typical for AD but there is poor correlation between 
the amount of plaques and the degree of dementia. 
Cerebral Aβ is generally cleaved by α-secretase and either degraded or 
cleared from the brain across the blood-brain barrier. Aβ peptide is gen-
erated by β- and γ-secretase induced cleavage of the amyloid precursor 
protein (APP), a transmembrane protein, forming predominantly Aβ1-40 
or Aβ1-42. According to the amyloid cascade hypothesis, AD is initiated 
by an imbalance in Aβ production and clearance (Hardy, 2009; Hardy and 
Selkoe, 2002). This hypothesis is supported by the finding that APP gene 
mutations around the α, β- and γ-cleavage sites and gene mutations in 
proteins involved in cleavage at the APP γ-site lead to increased Aβ pro-
duction and often early onset AD with an autosomal dominant pattern of 
inheritance. However, these mutations account for only < 5% of all AD 
cases. The other 95% of sporadic AD probably has a more complex mul-
tifactorial etiology (Minati et al., 2009).
Due to its fibrillogenic nature, high local concentrations of Aβ1-42 aggre-
gate into soluble oligomers. These oligomers cluster into larger insoluble 
Aβ fibrils that allow the formation of β-sheet structures, which are char-
acteristic for amyloid. This clustering of oligomers triggers the misfolding 
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Figure 2: Examples of diffuse plaques 
(arrows), classical plaques (arrow-
heads) and compact plaques (asterix).
of other Aβ species, including the more 
soluble Aβ1-40, forming plaques (Duyc-
kaerts et al., 2009). 
The study of Corder et al. suggested 
an acceleration of amyloid deposition in 
women of late middle age associated with 
APOE4 (Corder et al., 2004). In some 
AD mouse models, a similar sex-relat-
ed difference was found, showing more 
Aβ accumulation in female mice (Cal-
lahan et al., 2001; Wang et al., 2003). 
CAA
In the majority of AD cases different amounts of CAA are found in the 
brain (Natte et al., 2001; van Rooden et al., 2009; Weller et al., 2009). 
CAA is caused by the same Aβ deposits as in plaques, mainly Aβ 1-40 
and always forms amyloid which leads to stiffness and a loss of structure 
of the vesselwall. CAA can occur as a sporadic disease with little or no 
parenchymal Aβ deposits and is considered a major cause of cerebral mi-
crobleeds, haemorrhages and cognitive loss. 
 
Inflammation
In AD, microglia may play an important role in disease progression by ac-
tivating different inflammatory cytokines, causing neuronal damage and 
cell death (Doens and Fernandez, 2014; Hardy and Selkoe, 2002; Ketten-
mann et al., 2011). Microglia cluster especially around plaques and CAA.
Iron
Iron was recently identified as one of the pathological changes in the AD 
brain (Bartzokis, 2011; Meadowcroft et al., 2009; van Duijn et al., 2013). 
There are two hypotheses on the role of iron in AD. The first hypothesis 
claims that iron would directly contribute to the development of AD, due 
to its neurotoxic characteristics when not properly regulated (Bartzokis, 
2011). The second is the idea of iron deposits being secondary to the for-
mation of plaques and tangles (Peters et al., 2015); not playing a leading 
role in the development of AD, but following the formation of plaques. 
Iron also has relevance in AD research because it can be detected with 
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high sensitivity by magnetic resonance imaging (MRI) and may serve as 
an in vivo marker for AD.
 
Magnetic resonance imaging (MRI) and spectroscopy (MRS) in AD
The in vivo diagnosis of AD is now based on clinical and neuropsychologi-
cal criteria, with additional techniques such as neuroimaging and cerebro-
spinal fluid biomarkers playing a supportive role, resulting in “probable” 
AD at best. This diagnosis is not always accurate and needs post mortem 
histological confirmation (Fox et al., 1996; Hyman et al., 2012; Jack, Jr. 
et al., 2010). An MR-based hallmark for AD is hippocampal atrophy. This 
measurement, however, is neither conclusive nor specific for AD and con-
sequently of limited use in clinical setting (Nasrallah and Wolk, 2014). 
Furthermore, cerebral atrophy in AD is found in a late stage of the disease 
(Jack, Jr. et al., 2010) and therefore intrinsically a poor candidate for early 
diagnosis. Iron is a potential interesting target for the detection of early 
changes in AD. MRI is particularly sensitive to iron deposition in tissues, 
due to the changes it induces in the magnetic field.
Earlier studies demonstrated that increased iron accumulation in amyloid 
plaques induces a magnetic susceptibility effect. This is visible as hy-
pointens foci on T2*-weighted or susceptibility-weighted (SW) MRI in the 
cerebral cortex of transgenic AD mouse models and in human post-mor-
tem brain slices (Chamberlain et al., 2011; Meadowcroft et al., 2009; van 
Rooden et al., 2009). The high magnetic field strengths needed to obtain 
these results only recently became available for in vivo human use. These 
high field human MRI systems (> 7 Tesla) may offer new possibilities to 
specifically detect the neuropathological hallmarks of AD, with iron as 
main field of focus. Perhaps changes in iron distribution can be detected 
even at an earlier stage than the traditional hippocampal atrophy.
MRS is a non-invasive tool which can be used to measure the concentra-
tion of various brain metabolites in vivo (Marjanska et al., 2005; Oberg 
et al., 2008; Rupsingh et al., 2011). MRS uses MR to study the quantity 
of metabolites by measuring the interaction of a radiofrequency electro-
magnetic field with molecular nuclei inside an external high magnetic field 
(Azevedo et al., 2008). Measuring these metabolic changes in vivo, could 
help identify AD at an early stage since metabolic levels are believed to 
precede structural changes (Jack, Jr. et al., 2010). 
Numerous MRS studies have been performed in transgenic (tg) mouse 
models of AD. Several tg mouse models are available that develop sim-
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ilar, but not identical, pathology as compared to human AD. The results 
of previous MRS studies have shown AD-related abnormalities for several 
metabolites (Braakman et al., 2008; Chen et al., 2009; Choi et al., 2010; 
Dedeoglu et al., 2004; Marjanska et al., 2005; Oberg et al., 2008; von Kien-
lin M. et al., 2005; Westman et al., 2009; Xu et al., 2010). N-acetylaspar-
tate (NAA) in the brain is  predominantly present in neuronal cell bodies. 
Decreased NAA levels, indicating neuronal damage, have been found in 
tg mice in comparison to wild type (wt) mice (Chen et al., 2009; Choi et 
al., 2010; Dedeoglu et al., 2004; Marjanska et al., 2005; Oberg et al., 
2008; von Kienlin M. et al., 2005). Myo inositol (mIns) and taurine play a 
role in osmoregulation and are mainly found in astrocytes of brain tissue. 
These metabolites were found to be higher in tg mice than in wt mice 
(Chen et al., 2009; Choi et al., 2010; Dedeoglu et al., 2004; Marjanska et 
al., 2005; Westman et al., 2009). Glutamate (glu) is an excitatory neuro-
transmitter, involved in learning, memory formation, and cognition, which 
is found to be decreased in mice with AD (Braakman et al., 2008; Choi 
et al., 2010; Dedeoglu et al., 2004; Marjanska et al., 2005; Oberg et al., 
2008; von Kienlin M. et al., 2005). 
Tg mouse models allow monitoring of the pathological and metabolic 
changes from the onset of AD in a longitudinal study, which is an effec-
tive way to investigate the early changes in the AD brain. However, no 
longitudinal study has been performed on AD mouse models using the 
non-invasive technique of MRS. Following mice from birth and investigat-
ing metabolic changes using MRS, the early start of AD might be detected 
making treatment more effective and giving us more insight in the patho-
genesis of this disease. 
 
Scope of this thesis
The overall aim of this thesis was to investigate MRI-based early markers 
of AD. We focused on correlation of radiological findings in AD with histol-
ogy and we used MRS to study metabolic changes in brains of transgenic 
mice with AD. 
Chapter 2 describes the effects of prolonged formalin fixation on MRI sig-
nal of brain tissue. This is important because such long fixed material is 
more readily available than brain tissue which is fixed for less than a year. 
In chapter 3 we compare different histological techniques to visualize iron 
in human brain tissue. Selection of the best techniques is crucial for relia-
ble histological-radiological studies to assess the value of brain iron as an 
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MRI-based biomarker for AD.
Chapter 4 illustrates the relation between AD pathology and iron distribu-
tion in brain tissue of AD patients compared with normal aging subjects 
in different age groups. The difference of iron distribution between AD 
patients and aging was investigated in the frontal cortex.
Chapter 5 demonstrates a disturbed iron accumulation and myelin ar-
chitecture in AD using MRI with histological correlation on ex vivo brain 
tissue.
In Chapter 6 we describe the first systematic longitudinal MRS study to 
investigate the  differences in metabolic changes during development of 
AD in a transgenic mouse model.
Results of this thesis and recommendations for future studies are dis-
cussed in chapter 7. 
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Abstract
For the interpretation of magnetic resonance imaging (MRI) abnormalities 
in brain pathology, often ex vivo tissue is used. The purpose of this study 
was to determine the pathological substrate of several distinct forms of 
MR hypointensities that were found in formalin-fixed brain tissue with am-
yloid-beta deposits. Samples of brain cortex were scanned using effective 
transverse relaxation time-weighted protocols at several resolutions on a 
9.4T MRI scanner. High resolution MRI showed large coarse hypointensi-
ties throughout the cortical gray and white matter, corresponding to mac-
roscopic discolourations and microscopic circumscribed areas of granular 
basophilic neuropil changes, without any further specific tissue reactions 
or amyloid-beta related pathology. These coarse MRI hypointensities were 
identified as localized areas of absent neuropil replaced by membrane/
myelin sheath remnants using electron microscopy. Interestingly, the 
presence/absence of these tissue alterations was not related to amyloid 
deposits, but strongly correlated to the fixation time of the samples in 
unrefreshed formalin. These findings show that prolonged storaged of 
formalin fixed brain tissue results in subtle histology artifacts, which show 
on MRI as hypointensities that on first appearance are indistinguishable 
from genuine brain pathology. This indicates that postmortem MRI should 
be interpreted with caution, especially if the history of tissue preservation 
is not fully known.
Keywords: MRI, ex vivo, formalin
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Introduction
Magnetic resonance imaging (MRI) of postmortem brain tissue offers a 
valuable research method to study disease related changes in image con-
trast, because the findings can be correlated to histology (1-12).  High 
resolution ex vivo imaging has been a useful tool in interpreting the MRI 
features of many neurodegenerative disorders, including multiple sclero-
sis (MS), Alzheimer’s disease (AD), and (sporadic) cerebral amyloid angi-
opathy (1-3, 6-9, 11, 12). However, the MR characteristics of the tissue 
rapidly change in the postmortem situation because of tissue decomposi-
tion and chemical fixation; therefore direct translation of the findings to 
the clinical setting has to be done with caution (13-19). 
First, tissue decomposition occurs during the postmortem interval (PMI), 
the time period between the patient’s somatic death and beginning of the 
immersion-fixation of the tissue, which varies among subjects. Several 
studies have shown that an increasing PMI leads to a reduction of T1 
and T2 (13, 15, 20). However, a more recent study suggested that these 
findings might mainly be due to tissue dehydration or the fixative itself. 
When these effects were minimized, proton density, T1 and T2 values all 
increased with longer PMI (17). Also, mean diffusivity and fractional ani-
sotropy decrease with prolonged PMI (17, 21).
After autopsy, brain tissue will be immersed into a solution containing a 
chemical fixative, most frequently being formalin also known as formal-
dehyde. These solutions preserve tissue by slowly diffusing into it, leading 
to the cross-linking of proteins and immobilization of water molecules, 
thereby preventing autolysis and tissue decomposition (21-23). By its 
nature it is to be expected that this would affect MR characteristics, which 
indeed was confirmed by several postmortem brain MRI studies. A reverse 
in gray matter (GM)/white matter (WM) T1 contrast occurs within several 
days of fixation, merely due to a rapid decline in the latter combined with 
a general decrease in both continuing at least up to 3 months (18). Simi-
larly, T2 relaxation declines with prolonged fixation affecting both GM and 
WM, reaching a stable plateau as shown by consecutively imaging up to 6 
months fixation (13-15, 18).
All of the above has lead to important considerations on the correct meth-
od to obtain and interpret postmortem MR images (13, 15). 
However, similar studies investigating the effect of long fixation periods 
(> 6 months) on the MR characteristics have not yet been published. 
Nevertheless, this question is important, especially when using rare ma-
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terial from tissue archives, which are stored using fixatives like formalin 
for periods ranging from several years to decades. In a recent study us-
ing archival tissue with prolonged fixation times, we noticed unusually 
large coarse hypointensities, especially apparent on high resolution effec-
tive transverse relaxation time (T2*) weighted images, in several brain 
samples regardless of their pathological diagnosis. We hypothesized that 
these coarse hypointensities were the result of the extended formalin 
fixation period. 
Therefore, the purpose of this study was to investigate the occurrence 
of these T2* changes with respect to their formalin fixation time in brain 
samples with different pathologies. To this end, MR images were obtained 
of 18 samples with fixation times ranging from 3 months to several dec-
ades. Subsequently, the samples were evaluated both macroscopically 
and microscopically to identify the occurrence and the microscopic sub-




We used brain tissue of six patients with AD, four patients with Hereditary 
Cerebral Haemorrhage with Amyloidosis, Dutch type (HCHWA-D), two pa-
tients with Down’s Syndrome (DS), two patients with sporadic Cerebral 
Amyloid Angiopathy (CAA) and four control brains (Table 1). The brain 
tissue had been routinely immersed in buffered 10% formalin for several 
weeks to 6 months after which the wet tissue was archived in sealed plas-
tic bags with a small excess of 10% formalin. Total fixation times varied 
from 4 months to 42 years. From a subset of subjects, several samples of 
the exact same brain had also been paraffin embedded at the beginning of 
their fixation process, normally within 1 month postmortem. This allowed 
a direct comparison of structural changes with tissue from the same pa-
tients that was archived in formalin and embedded in paraffin several 
years later (Table 2).  
Magnetic Resonance Im-
aging
A slice of 20x15 mm brain 
tissue was selected from 
each subject and cut into 
a 4-mm-thick slice using a 
vibratome (VT1000S, Leica 
Microsystems, Wetzlar, 
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Figure 1: Similar T2* weighted MR images of subject 14 acquired with isotropic reso-
lution of respectively A) 40 µm, B) 100 µm, C) 200 µm and D) 400 µm. Many coarse 
hypo intensities are detected in the higher resolution, but even in D) hypo intense 
voxels correlate back to them (white arrows). E) Shows the calculated T2* map of the 
section in B) with the previously seen hypo intensities having a lower T2* then the 
surrounding tissue. 
Germany). The 4-mm slice was placed in a custom made tissue holder, 
immersed in a proton-free fluid (Fomblin, Solvay, Solexis, Milan, Italy) 
and positioned in a vertical small-bore 9.4T Bruker Avance 400WB MRI 
system, equipped with a 1T/m actively-shielded gradient insert and Para-
vision 4.0 imaging software (Bruker Biospin, Ettlingen, Germany). A 20-
mm birdcage transmit/receive coil was used (Bruker BioSpin). Several 
three dimensional T2*-weighted gradient echo sequences were obtained 
with isotropic resolutions of 40 – 100 – 200 – 400 µm with the number 
of signal averages being 60 – 20 – 20 – 12 respectively, echotime/pulse 
repetition time = 12.26 / 75 ms, flip angle = 25º. With the matrix size 
depending on the shape of each sample, average scan time per resolution 
were 28 hrs, 2 hrs 40 min, 20 min. and 8 min respectively. For quanti-
tative T2* measurements, 100 µm scans were also acquired using echo 
time =  8 – 10 – 12.26 – 15 ms.  
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Figure 2: Images from subject 13 showing A) fixated brain tissue with white dis-
colourations (white arrows) and B) high resolution (40µm) T2* weighted MR im-
ages of the same brain tissue with coarse hypo intensities (white arrows). 
Histology
Following MRI, brain slices were paraffin-embedded and serially cut in 
8-µm sections. Consecutive sections were stained for general microscopic 
morphology (hematoxylin and eosin (HE)), for myelin (Kluver-Barrera), 
for iron (Perls and a modified Perls DAB) (24), (FEIII-DAB, FEII-DAB) 
(25), copper (Romeis) and immunohistochemistry for Aβ (Dako, 6F/3D) 
(26), and glial fibrillary acidic protein (GFAP) (Dako, 6F2) (27). To allow 
correlation with MRI, sections were digitalized using a flatbed scanner 
(Agfa).
Electron microscopy
Electron microscopy was performed on a subset of subjects (Table 2) as 
previously described (28). Collection was done on copper grids instead of 
carbon grids. Sections were examined using a JEOL JEM-1011 electron 
microscope operating at 60 kV and digitalized using a MegaView III cam-
era.
Analysis / Scoring
Two sequential MR slices from the three dimensional data sets at 40 um 
resolution were examined for “coarse” hypointensities defined by large 
size (120-1200um), irregular contour and elongated to stellate shape. 
These coarse hypointensities were scored as follows: absent: 0 coarse 
hypo intensities, present: 1-9 coarse hypointensities, extensive: ≥10 
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Figure 3: Images of subject 17. Comparison of MR image with HE staining and Aβ staining 
correlating the granular neuropil changes with the hypointensities in the MRI. The rectan-
gles are the locations of 10x magnifications 1, 2 and 3. Showing that granular neuropil 
changes can be found at the same location as the hypo intensities but without amyloid 
deposition. Scale bars are given. A: HE staining; B: MR image; C: Aβ staining
coarse hypointensities. Three HE stained sections from the same level 
of the two sequential MRI slices were used to correlate MR images with 
histology. To perform these correlations, we used Adobe Photoshop 6.0 
to visually overlay digitalized histological sections to their corresponding 
MR images. Of each patient, the same HE sections were used to score 
the amount of granular neuropil changes as follows: absent if no granular 
neuropil changes were found, present for 1-4 and extensive for ≥ 5 neu-
ropil changes in at least one out of the three sections.
Subjects with similar score were combined for group analysis (Mann-Whit-
ney) to find significant differences (P-value < 0.05) in fixation period and 
age (SPSS 17).
 pH of formalin
Of five patients with widely variable fixation times (Table 3), the pH of the 
formalin around the brain slices in sealed plastic bags was determined 




High resolution T2*W images of 11 subjects showed irregularly con-
toured, elongated and stellate shaped hypointensities that were randomly 
distributed throughout the cortical gray matter and to a lesser degree in 
the white matter (Fig.1A). Their typical size (120 – 1200µm) and char-
acteristic shape allowed clear distinction from possible other brain struc-
tures known to have a similar effect on T2*, e.g., blood vessels or small 
roundish hypointensities caused by amyloid-β (Aβ) plaques, especially 
when including their spatial orientation (Fig.4). Based on these character-
istics, we defined them as “coarse hypointensities” and tissue was scored 
according to their presence (Table 1).
When comparing similar MR images of the same section at decreasing 
resolution (Fig.1A-D), these coarse hypointensities became less pro-
nounced and harder to recognize as such. This depended on their actual 
size and shape being affected by partial volume effects due to increasing 
voxel size. High and low resolution data were compared with assess, if 
hypointense voxels on low resolution scans correlated with coarse hypoin-
tensities at high resolution. The largest coarse hypointensities were also 
visible at the lowest isotropic resolution of 400 µm, which is comparable 
to the in vivo MRI resolution (Fig.1D). On quantitative T2* maps, areas 
containing coarse hypointensities caused a clearly noticeable decrease in 
T2* (Fig. 1E). 
Pathology
Macroscopy
Only in brain tissue with coarse hypointensities on MRI, well circumscribed, 
white discolourations with similar size and distribution as the coarse MRI 
hypointensities were observed (Fig. 2, Table 1).
Histology
Microscopically, HE sections of tissue blocks with macroscopic white dis-
colourations showed neuropil alterations with a close spatial correlation 
to the coarse MRI hypointensities (Fig. 3 and 4). These neuropil altera-
tions comprised irregular, well circumscribed areas of granular, basophilic 
changes usually with some tissue rarefaction (Fig. 5). The corresponding 
Kluver’s staining within these areas was decreased with respect to sur-
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Figure 4: Images from subject 18. Comparison 
of MR image with HE staining and Aβ staining. 
Showing granular neuropil changes in the white 
matter without Aβ deposition and plaques com-
bined with these changes. The rectangles are 
the locations of the magnifications. Scale bars 
are given. A: MR image; B: HE staining; C: Aβ 
staining; 1B: 10x magnification of the HE stain-
ing showing the granular neuropil changes in 
the white matter; 1C: 10x magnification of the 
Aβ staining showing these changes in the WM 
without Aβ deposition. 2C: 5x magnification of 
the Aβ staining, showing the granular neuropil 
changes with plaques and only plaques.
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Figure 5: HE 20x 
Granular neuropil 
changes 
rounding cortex/white matter suggesting a lower density of myelin. Most 
of these areas showed birefringence under polarized light in the HE that 
was not seen in unstained sections or the Kluver’s stain that excludes the 
presence of anorganic material. The areas of basophilic granular neuropil 
changes were randomly distributed throughout the cortex and increas-
ingly present in the white matter of tissue with long fixation times. These 
areas were found around vessels but also apart from vessels. The baso-
philic granular neuropil changes showed no signs of gliosis, haemorrhag-
es or infarcts. Neurons, astrocytes, microglia and vessels were normally 
distributed within these areas and morphologically unaltered. Gemisto-
cytes were not present. Furthermore, all (immuno) histological stainings 
for iron, copper and amyloid-β were negative within these areas (Fig. 4).
The basophilic granular neuropil changes were found not only in AD ma-
terial but also in long fixated brain tissue of controls (Fig. 3 and 4). In 
contrast, these changes were not found in short fixated AD material. 
Apart from the coarse hypointensities that co-localized with neuropil de-
generation, other small roundish hypointensities were observed on MRI 
that did correspond to amyloid plaques (Fig. 4).
Electron microscopy
Tissue with macroscopic white discolourations showed localized areas 
with absent neuropil, although vessels were often present in these spac-
es on 1 µm -thick, epoxy embedded tissue sections stained with tolu-
idine blue. Electron microscopy of immediately adjacent ultrathin sec-
tions showed that these areas with absent neuropil actually consisted of 
spaces without any neuropil or only little neuropil remnants (Fig. 6A). 
However, in these spaces varying amounts of lamellar structures were 
38
found, which were interpreted as membrane remnants and/or swollen 
degenerated myelin sheaths (Fig. 6B-C). Outside these circumscribed ar-
eas, we observed variable splitting and swelling of myelin sheets ranging 
from little splitting in otherwise normal myelin sheaths around axons, to 
swollen myelin sheaths lining small empty spaces within the neuropil (Fig. 
6D-E).  
 
Relation of coarse MR hypointensities with fixation duration
The presence of coarse MR hypointensities, macroscopic and microscopic 
abnormalities were scored for each subject and the results are shown in 
Table 1. Subjects with similar scores were combined for group analysis.
With regard to coarse MR hypointensities, fixation periods were signifi-
cantly shorter when scored “absent” compared to “present” (P-value = 
0.017 / r = -0.79). Furthermore, with even longer fixation periods, the 
number of hypointensities significantly increases when comparing “pres-
ent” with “extensive” (P-value = 0.018 / r = -0.71). 
Similar results were obtained when comparing groups with different 
scores for granular neuropil changes. Fixation periods of those scored 
“absent” were significantly shorter when compared with those who scored 
“present” (P-value = 0.006 / r = -0.82), which was significantly shorter as 
compared to “extensive” cases (P-value = 0.008 / r = -0.80). 
No significant differences in subject’s age between groups were found for 
either coarse hypointensity, histological or macroscopic score. Further-
more, no correlation was found between coarse MR hypointensities and 
presence/absence of disease regardless of type of disease.
In summary, brain tissue showed no changes when fixed for a period of 
< 1 year in the same formalin solution, whereas changes were always 
present in tissue fixed for a period of > 6 year, and increasingly so with 
longer fixation periods.
To test the hypothesis that prolonged formalin fixation indeed leads to 
histological and MR detectable changes, brain tissue from the same sub-
ject that was formalin fixed for either a short or a much longer period 
was compared microscopically (Table 2). In the long-term fixed material, 
macroscopic white discolourations and granular neuropil changes were 
present, whereas short-term fixed material of the same subject complete-
ly lacked these findings, indeed supporting our hypothesis.
To obtain a complete picture, pH measurements were performed, because 
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Figure 6: Ultrastructure of localized areas of nearly empty spaces on semithin sections in 
long term formalin fixed tissue with macroscopic white discolourations. A) These areas con-
sisted of spaces without neuropil or only little neuropil remnants and often but not always 
contained a small blood vessel (1200X) B) Circumscribed area of absent neuropil showing 
lamellar structures and a capillary (arrow) (1200X). C) Lamellar structures in B (15000X). 
D) myelinated axons, some with splitting of the myelin sheath. One axon (arrowhead) 
shows myelin splitting (large arrow) with little expansion of the spaces between the myelin 
sheaths (small arrow) (15000X). E) myelinated axon partly with intact myelin sheath and 
partly with myelin splitting with transition to more laminated structures with increasing 
spaces between the lamellae.
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formalin solutions are known to become more acidic over time. pH meas-
urements indeed showed increased acidity after longer periods of formalin 
fixation, as observed in the sealed plastic bags used for tissue storage 
(Table 3). 
Discussion and Conclusion
In this study, “coarse hypointensities” on postmortem brain MRI were 
seen corresponding to localized areas of neuropil destruction with rem-
nants of membranes and myelin sheaths as observed by electron micros-
copy. These coarse hypointensities are mainly detected at high-resolution 
MR scans. Although brain tissue from Aβ-related diseases was used, the 
hypo intensities where not related to deposits of iron, copper or Aβ cor-
relating with these neurological diseases. Instead, these hypointensities 
appear to be an art1fact associated with the duration of fixation within the 
same formalin. This can be concluded from the findings that these hypoin-
tensities were also detected in control tissue with long fixation times, and 
were not found in disease-related tissue fixated for a short period. 
The exact mechanism of the described storage related art1facts is not 
known from previous studies, but formalin solutions are known to become 
more acidic over time (29). This was confirmed by pH measurements of 
the excess formalin around our sealed fixed brain tissue. Possibly neuropil 
destruction is caused by a local increase of acidity. However, continuous 
exposure to formalin and/or formic acid may form many other compounds 
that possibly play a role in causing artifactual tissue changes (29, 30). 
We were not able to study the effect of long term fixation in regularly 
refreshed formalin, and we can thus not exclude prolonged immersion in 
formalin itself as a cause of local neuropil destruction leading to MR hy-
pointensities rather than the increasing acidity or the formation of aggres-
sive metabolites. Postmortem autolysis does not appear to be the cause 
of the artifacts we have observed.
For this study, sufficient material fixed for a period of 1-6 years was lack-
ing. Consequently, we can only conclude that neuropil artefacts occur in 
all tissue stored for a period of at least 6 years within the same formalin, 
whereas tissue stored for a period of <1 year showed no changes.
The coarse hypointensities correspond macroscopically to homogeneous 
white discolourations in the tissue, and microscopically in 8µm HE sec-
tions to granular neuropil alterations with slightly less density than the 
surrounding neuropil. The ultrathin sections (90 nm thick) used for EM re-
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vealed that these areas represented absent neuropil with partial filling of 
the resulting spaces by membrane-like structures. We speculate that this 
degenerated membranous/proteineous material with weak birefringence 
causes hypointensities on MRI because of its solid-state-like properties. 
The low signal intensity on MRI may also result from replacement of for-
malin solution by proton free fluid in these relatively more empty spaces. 
However, a decrease in proton density would not cause a T2* decrease, 
as was observed in the T2* maps.
With respect to the induced MR changes, previous reports state that 
formalin fixation causes changes in relaxation and diffusion properties, 
thereby altering MR contrast, even though the exact mechanism remains 
unclear (16). However, these changes in MR properties occur throughout 
the entire sample and are partially reversible by rehydrating the sample 
in PBS. In contrast, the structural disruptions we found after prolonged 
formalin fixation are very localized and irreversible. Furthermore, detect-
ed changes were not related to any of the known possible changes due to 
prolonged PMI as described elsewhere (13,15,17,20,21). For this study 
brain tissue of all kinds of PMI periods was used, and no correlation was 
found with either the tissue changes or MRI hypointensities (Table 1).
The conclusion of this study suggests that data of several earlier published 
studies, using postmortem brain tissue of patients with AD for MRI (1-12), 
should be cautiously interpret. In these studies, hypointense spots were 
observed on T2* or T2-weighted scans that co-localized with dense amy-
loid plaques and iron accumulations (1-12). However, brain tissue in these 
studies was collected within a short period, and fixed for a maximum pe-
riod of a few months. 
With regard to the detection of amyloid plaques, we also observed hy-
pointense spots on MRI that corresponded to the presence of amyloid 
plaques. However, these did not correlate with the larger stellar shape 
coarse hypointensities (Fig.4). The possible Aβ plaque detection indicates 
that the basic mechanisms for MR contrast (iron accumulation and dense 
protein aggregates) are still present. On ultrahigh resolution scans, these 
different hypointensities can be easily distinguished. However, on scans 
with a lower resolution, e.g., those comparable with resolutions that can 
be achieved on clinical MRI systems, both forms might become indistin-
guishable, and based on their size the coarse hypointensities because 
of fixation artifacts are more likely to remain visible (Fig. 1D). In our 
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study, these low resolution images were acquired at relatively short echo 
times; when a stronger T2*-weighting would be used, more hypointen-
sities would be observable at these lower resolutions. Furthermore, it is 
important to realize that although these neuropil changes are beyond the 
anatomical resolution of scans with clinical resolutions, they could still be 
visible on such scans because their signal differs so strongly from sur-
rounding tissue. 
Other known sources for hypointensities on T2*-weighted images, like 
calcifications, iron deposits, microbleeds or cavernous malformations 
(31) could be easily disregarded within this study, whereas their presence 
could not be confirmed on histology. However, especially when conduct-
ing similar ex vivo MR studies for either one of these pathologies using 
old brain material and clinically relevant resolutions, one should be aware 
that the described formalin fixation artifacts could possibly lead to similar 
hypointensities and thus a misinterpretation of the data.
To put our findings into a broader perspective, a small survey was con-
ducted among eight other brain banks and neuropathology departments 
regarding their brain storage protocol. Three of these centres store their 
formalin-fixed brain tissue in sealed plastic bags with little excess formalin 
similar to the tissue used in this study, whereas four other centres store 
fixed brain tissue floating in formalin, two without a protocol for regular-
ly refreshing it, one renewing formalin “when necessary” and the fourth 
every few years. The last centre stores brains in polyethyleenglycol. How 
the different storage protocols affect the general tissue quality with re-
spect to ex vivo MRI research after long term storage remains to be fur-
ther investigated, but this small survey shows that the fixation protocol 
for our study is common practice among brain banks, and therefore the 
findings will have implications for future research on brain bank tissue. 
In conclusion, our results demonstrate that fixed brain tissue stored for 
prolonged periods gives rise to structural tissue changes that are associ-
ated with hypo intensities on T2*-weighted MR images. When brain tissue 
from pathology archives or brain banks is used to study (rare) disorders 
with ex vivo MRI, it is of vital importance to take the storage protocol into 
account and to check for the macroscopic and microscopic alterations that 
have been described and illustrated in this study.
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Abstract
Better knowledge of the distribution of iron in the brains of Alzheimer’s 
disease (AD) patients may facilitate the development of an in vivo mag-
netic resonance (MR) marker for AD and may cast light on the role of this 
potentially toxic molecule in the pathogenesis of AD. Several histological 
iron staining techniques have been used in the past but they have not 
been systematically tested for sensitivity and specificity.
This article compares three histochemical techniques and ferritin immu-
nohistochemistry to visualize iron in paraffin embedded human AD brain 
tissue. The specificity of the histochemical techniques was tested by stain-
ing sections after iron extraction.
Iron was demonstrated in the white matter, in layers IV/V of the fron-
tal neocortex, in iron containing plaques, and in microglia. In our hands 
these structures were best visualized using the Meguro iron stain, a meth-
od that has not been described for iron staining in human brain or AD 
in particular. Ferritin immunohistochemistry stained microglia and iron 
containing plaques similar to the Meguro method but was less intense in 
myelin associated iron. The Meguro method is most suitable for identify-
ing iron positive structures in paraffin-embedded human AD brain tissue.




There is growing evidence that iron plays an important role in the devel-
opment of neurodegenerative diseases such as Alzheimer’s disease (AD). 
One of the reasons is an altered brain iron distribution with iron accumula-
tion in AD plaques (LeVine 1991; Smith et al. 1997; Crichton et al. 2002; 
Haacke et al. 2005; Meadowcroft et al. 2009; Bartzokis 2011). These 
disease-related changes in brain iron distribution are a potential marker 
for early in vivo diagnosis using MRI, especially because recent advances 
in human magnetic resonance imaging (MRI), systems operating at an 
ultra-high magnetic field (7 Tesla and higher) show increased sensitivity 
to iron-based susceptibility contrast in the human brain that have not 
been observed before (Nabuurs et al. submitted). A validated histological 
method to stain iron in brain tissue is required to correlate the MRI find-
ings with histological changes in iron distribution and to study the role of 
iron in the development of neurodegenerative diseases like AD. 
Iron (Fe) is essential for the proper functioning of many cellular process-
es. Due to its capability to catalyze oxidation-reduction reactions, iron 
serves as an active site in molecules with critical biological functions. 
However, this also requires a strict regulation to prevent uncontrolled 
spreading of catalytic active iron and its potential (neuro) toxicity (Me-
guro et al. 2007). This regulation is achieved by strong binding between 
iron and the proteins transferrin and ferritin. Transferrin, a transporter 
protein, can bind two Fe3+ ions. Ferritin serves as the principle iron stor-
age protein capable of binding up to 4500 iron atoms in different mineral 
forms, predominantly as Fe3+ and small amounts of Fe2+ (Meguro et 
al. 2007). In organisms iron can be categorized as heme or non-heme 
iron. Heme iron is a Fe2+ protoporphyrin complex found in, for instance, 
haemoglobin. Non-heme iron consists of Fe3+ bound to ferritin or trans-
ferrin and very small amounts of Fe3+ and Fe2+ loosely bound to organic 
bases, enzymes, iron sulphur proteins and nucleotides. In general, nearly 
all non-heme iron found in the human body is bound to ferritin as Fe3+. 
The distribution of ferritin closely resembles the distribution of iron and 
therefore may act as a surrogate marker for iron (Grundke-Iqbal et al. 
1990;Meguro et al. 2007). 
In the normal brain, most iron is present in myelin and oligodendrocytes 
which require irondependent enzymes to produce and maintain myelin. 
Myelin-rich areas such as white matter thus contain large amounts of 
iron. In the cerebral cortex, iron is also expected in the myelin-rich layers 
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IV and V (Fatterpekar et al. 2002). In damaged brain tissue, microglial 
cells have been shown to accumulate iron (Schonberg et al. 2012).
Non-heme iron (predominantly in the Fe3+ form) can be visualized in 
paraffin embedded tissue by the classic Perl’s iron stain, in which soluble 
ferrocyanide reacts with the tissue Fe3+ to form crystals that make an 
insoluble Prussian blue dye. Further enhancement can be obtained by 
allowing the Prussian blue crystal to catalyze the H2O2-dependent oxida-
tion of diaminobenzidine (DAB) (Meguro et al. 2007). Several protocols for 
DAB-enhanced iron stains, using different pre-treatment, slide thickness, 
endogenous blocking and reagent concentrations have been published but 
these different methodologies have never been directly compared with 
one and another and only some staining patters have been related to fer-
ritin immunohistochemistry (IHC) (Barbeito et al. 2009; Butt et al. 2010; 
Fukunaga et al. 2010; Chen-Roetling et al. 2011; Shpyleva et al. 2011) 
or checked for false positive results in iron depleted sections (Smith et al. 
2007). The DAB enhanced histochemical iron stains described by Smith 
(Smith et al. 1997) and LeVine (LeVine 1991) have been reported to la-
bel AD plaques. The Meguro method (Meguro et al. 2007) has not been 
described in human brain tissue or animal models of AD but has been 
widely used in other organs in rat, mice and monkey (Meguro et al. 2005; 
Meguro et al. 2007; Freret et al. 2008; Iwatsuki et al. 2008; Meguro et 
al. 2008; Butt et al. 2010;Winter et al. 2010; Butt et al. 2011; Shpyleva 
et al. 2011). 
The purpose of the present study is to compare the Meguro, Smith, and 
LeVine iron staining methods for detection of non-heme iron in brain tis-
sue with AD pathology. In addition, we investigated their correlation with 




One block of formalin-fixed, paraffin embedded brain tissue of the frontal 
cortex of 4 AD patients (60-87 y; Braak 6: N = 2; Braak 5: N = 1; Braak 
4: N = 1) and 4 control patients without dementia of evidence of AD (62-
76 y; Braak 0) was used. Samples were handled in a coded fashion to 
maintain anonymity according to Dutch national ethical guidelines. The 
brain tissue had been routinely immersed in buffered 10% formalin for a 
maximum of 6 months. 
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Figure 1: Comparison of the Meguro (1), Smith (2), LeVine (3) and ferritin IHC (4) in con-
trol patients (A and B) and AD patients (C and D). A: whole section of a control patient 
(scale bar 5000 µm); B: 20x magnification of A (scale bar 100 µm); C: whole section of 
an AD patient (scale bar 5000 µm); D: 20x magnification of C (scale bar 100 µm). Arrows 
indicate examples of iron positive plaques; arrowheads indicate examples of microglia; 
double arrows show layer IV/V of the cortex.
Iron extraction
In the first experiment, the tissue of AD patients was used to examine 
the effect of iron extraction on the different stainings. For each patient 
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sample 7 serially cut 10 µm thick sections were mounted onto slides. Of 
each of these series, section 1, 3 and 5 were incubated with 250 μl 0,1 M 
Na-citrate/HCL pH 1,0 buffer (Boom BV, Meppel, The Netherlands). After 
overnight incubation, the buffer was aspirated from the section and its 
iron concentration was measured using the Cobas Integra 400/800 meth-
od (Roche Diagnostics, Mannheim, Germany). As a control, the iron con-
centration was tested in the native buffer, in buffer incubated on a glass 
slide without tissue and in buffer with Fe3+ (Menck BV, Amsterdam, The 
Netherlands) added as a positive control. The limits of sensitivity of the Fe 
elution assay are 0,9-179 µmol/L (Roche Diagnostics).
As a control experiment the tissue of AD patients was used to test the iron 
extraction capability of Na-citrate/HCL buffer. Of each patient sample a 
section was incubated with 250 µl 0,05 M TRIS/HCL pH 1,0 buffer (Menck 
BV) and an adjacent section was incubated with 250 µl 0,1 M Na-citrate 
pH 1,0 buffer to extract iron. After overnight incubation, the buffer was 
aspirated from the section and its iron concentrations was measured as 
described above. 
Histological procedures for iron staining
For the first experiment, the sections of AD tissue as described above 
were used. Of each patient sections 1 and 2 were stained as described by 
Meguro et al. (Meguro et al. 2007) with an increase in incubation times 
of 25%: after de-waxing/rehydration the paraffin sections were incubated 
for 40 min in 1% potassium ferrocyanide, washed and treated in meth-
anol containing 0.01 M NaN3 and 0,3% H2O¬2 for 75 min. Then the 
sections were treated in 0.1 M phosphate buffer, followed by a solution 
containing 0.025% 3,3’-DAB-4HCL (DAB, Sigma, St Louis, MO, USA) and 
0.005% H2O2 in a 0.1 M phosphate buffer for 40 min. The reaction was 
stopped by washing.
The third and fourth sections were stained according to Smith et al. (Smith 
et al., 1997) In short, after deparaffinization in xylene and rehydration 
through graded ethanol, sections were incubated for 15 hrs in 7% potas-
sium ferrocyanide in aqueous hydrochloric acid (3%) and subsequently 
incubated in 0.075 % 3,3’-DAB and 0.015% H2O2 for 5–10 min.
The fifth and sixth sections were stained according to Levine et al. (LeV-
ine 1991) but with an increased DAB incubation time of 1 hour and 45 
minutes. Briefly, after deparaffinization and rehydration the sections were 
incubated in 10 mg NaBH4/ml PBS, 30 min, washed in PBS and incubated 
in 30 ug protK/ml PB S with 0.1% Triton X-100, 20 min, at room temper-
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Figure 2: Comparison of the Meguro (1), Smith (2), LeVine (3) to ferritin IHC (4) on AD 
tissue. A: whole section (scale bar 5000 µm); B: 10x magnification (scale bar 200 µm); C: 
40x magnification of 2 (scale bar 50 µm); D: 40x magnification (scale bar 50 µm). Arrows 
indicate examples of iron positive plaques; arrowheads indicate examples of microglia; dou-
ble arrows show layer IV/V of the cortex.
ature. Sections were washed in PBS and incubated in 1% potassium fer-
rocyanide/1% Triton X-100/0.125 N HCL, 30 min. Sections were washed 
in PBS and incubated in a mixture of 1 mg DAB: 5 ml 0.01M Tris HCl pH 
7.6: 10 ul 30% H2O2 for 2 hours in the dark followed by washing in PBS. 
The seventh section was stained immunohistochemically for ferritin using 
polyclonal anti-ferritin rabbit antibody at 1:10000 (Bethyl, Montgomery, 
Texas, USA) overnight, followed by a swine anti-rabbit biotin (Dako) 1:600 
for 1 hour at room temperature. After washing with PBS, immunolabelling 
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followed using an ABC kit (Vectastain) according to the manufacturer’s 
instructions and visualized with DAB (3’3 diaminobenzidine, Sigma).  The 
concentration of ferritin rabbit antibody 1:10000 was chosen after a series 
of 7 different concentrations. 1:100, 1:500, 1:1000, 1:5000, 1:10000, 
1:20000, 1:40000. The dilution of 1:10000 gave the most optimal signal 
compared to the higher and lower concentrations.
In the second experiment the three different methods and the ferritin IHC 
were performed on tissue of AD patients and on tissue of control patients. 
The tissue was cut in 10 µm thick sections and  mounted onto slides. Ad-
jacent sections were stained with the Meguro, Smith and LeVine method 
and the ferritin IHC as described above.
Scoring
All sections were scored for iron/ferritin labelling of plaques, microglia, 
white matter and cortical layers IV and V. Microglia cells were defined as 
iron positive cells with dilated cell bodies and dilated cellular processes. 
We and others have shown that iron positive cells with this morphol-
ogy label for microglial immunohistochemical markers (Nabuurs et al. 
2011; Schonberg et al. 2012). The intensity of iron and ferritin staining in 
plaques and microglia was scored as: no staining (-), intermediate stain-
ing (+) or strong staining (++). Labelling of myelin-associated iron in the 
white matter and the myelin rich cortical layers IV and V was scored as 
no contrast (-), intermediate contrast (+) and strong contrast (++) ver-




The Meguro method showed the strongest contrast between gray and 
white matter in AD and control tissue (fig 1 and 2). This contrast was 
also seen using the Smith and LeVine staining, however, it was less pro-
nounced. Cortical layers IV and V showed the most intense labelling by 
the Meguro stain, and labelling of these layers was more pronounced in 
AD than in controls. These layers were also seen to a lesser extent in the 
Smith staining but not in the LeVine staining. Iron-containing plaques and 
microglia in AD tissue were most frequently and most intensely labelled 
by the Meguro stain. The Smith method detected less microglia and fewer 
iron containing plaques in the cortices of AD patients. The LeVine meth-
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Figure 3: The Meguro (A), Smith (B), LeVine (C) method with iron extraction as pre-treat-
ment (1) and without iron extraction as pre-treatment (2) on AD tissue; scale bars 5000 µm.
od was clearly the least sensitive, showing no enhanced labelling of the 
cortical layers IV/V, only a few plaques and no microglia. No iron positive 
plaques or microglia were found, with any of the iron staining methods, 
in control tissue. 
Comparison with ferritin IHC
The Meguro method and ferritin IHC showed a comparable distribution 
and frequency of iron-positive plaques and microglia in AD tissue but the 
plaques looked different. Both methods showed plaques with clustered 
iron positive microglia, but the extracellular parenchymal plaque deposits 
were labelled differently. The Meguro method showed intense and sharply 
circumscribed labelling of extracellular plaque deposits, whereas ferritin 
IHC showed weak, diffuse labelling of these deposits (fig 2). The contrast 
between white matter and cortex and the visibility of cortical layers IV/V 
was better using the Meguro iron stain than in ferritin IHC in both AD tis-
sue and control tissue. Higher concentrations of the antibody gave more 
background with less contrast between the different layers in the cortex 
and between white and grey matter.
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Table 1: Comparison of LeVine, Smith, Meguro iron stain and ferritin Immunohistochemistry. 
Each score represents the aggregated result of the 4 patients. For iron positive plaques and 
microglia: - = no staining; + = intermediate staining; ++ = strong staining. For contrast 
between cortical layers IV/V and the other cortical layers and for contrast between white and 
grey matter: - = no contrast; + = intermediate contrast; ++ = strong contrast. 
Iron extraction
None of the three investigated procedures showed staining of any cell 
or structure in tissue after iron extraction (fig 3), but all showed their 
usual staining pattern in the parallel section without iron extraction as a 
pre-treatment. Only the LeVine method showed a light background stain-
ing and lacked contrast between white matter and grey matter.  
The buffer incubated with tissue showed much higher iron concentrations, 
than buffer incubated on a glass slide without tissue, confirming iron ex-
traction (table 2).
Iron extraction with Na-citrate/HCL buffer gave better results compared 
with the TRIS/HCL buffer on the tissue. However, after adding Fe3+ to the 
buffer the results were better using TRIS/HCL as a buffer.
Discussion
To our knowledge, this is the first study to provide a direct comparison 
of three frequently used histochemical iron stains on human paraffin-em-
bedded AD brain tissue and simultaneously investigates changes in the 
distribution of ferritin. We evaluated their ability to stain iron-containing 
plaques and microglia as well as myelin-associated iron. The method ac-
cording to Meguro et al. (Meguro et al. 2007) resulted in the most robust 
and intense labelling of these iron containing structures.
We are not aware of earlier studies using the Meguro method to visualize 
iron in human brain tissue, but it has been described for the detection 
of iron in paraffin-embedded tissue of rat, mice, monkey and guinea pig 
(Meguro et al. 2005; Freret et al. 2008; Iwatsuki et al.  2008; Meguro et 
al. 2008; Butt et al. 2010; Winter et al. 2010; Butt et al. 2011; Shpyleva 
et al. 2011). 
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Table 2: quantification of iron present 
in the extraction buffer after incubation; 
These results were not corrected for the 
amount of tissue that was incubated. 
The Smith method (Smith et al. 1997) showed moderate amounts of mi-
croglia and plaques with less intensity than the Meguro stain. The staining 
of cortical layers IV and V was weak. With this method plaques have been 
demonstrated on 6 to 8 µm paraffin sections (Smith et al. 1997;van Duijn 
et al. 2011). Labelling of iron in microglia has not been described in ear-
lier reports. This method differs to that described by Meguro et al. in its 
exclusion of the methanol-NaN3-H2O2 treatment step between the ferro-
cyanide and DAB amplification step as well as the much longer (overnight 
versus 30 minutes) incubation time, with a 7 fold higher concentration of 
ferrocyanide and a shorter incubation with DAB in a 3x higher concentra-
tion. How these differences result in a less intense labelling of iron-posi-
tive structures than that by the Meguro method remains unclear. For the 
protocol used by Smith et al. methacarn fixation has been described to 
result in better iron labelling than formalin fixation. We performed the 
Smith protocol on formalin-fixed tissue because in our and most other 
laboratories tissue is routinely fixed by formalin; thus a general iron stain-
ing should be optimized preferably for formalin fixed tissue. 
The last technique, published by LeVine (LeVine 1991), showed the least 
intense staining of the scored characteristics or no staining at all. Earlier 
studies showed plaques using this method on 60- to 100-µm free-float-
ing sections (LeVine 1997; Meadowcroft et al. 2009) and iron-containing 
microglia in multiple sclerosis brains (LeVine 1997). No results of iron in 
layers IV/V have been reported using this method. The most likely expla-
nation for the inferior labelling of plaques in the LeVine method compared 
to the other stains is our use of 10-µm de-paraffinized sections on glass 
slides whereas the LeVine method has been developed for 60- to 100-µm 
free-floating sections (LeVine 
1991; LeVine et al. 1992; LeV-
ine et al. 1993). The absence of 
labelling of cortical layers IV and 
V may be due to the aggressive 
pre-treatment releasing iron 
from the myelin which is slightly 
increased compared to the other 
layers.  
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Using the Meguro technique, the contrast between white and grey matter 
and between cortical layers IV/V and the other cortical layers was more 
intense than using ferritin IHC. This may be due to problems with antigen 
retrieval in myelin-containing tissue. A problem of antibody sensitivity 
seems unlikely because intracellular microglial staining is very strong and 
frequent in ferritin IHC, similar to that observed with the Meguro iron 
stain. The differences between the Meguro iron stain and the ferritin IHC 
remained when higher or lower ferritin antibody concentrations were used. 
Alternatively, there may be a true difference between the presence of iron 
and ferritin in myelin due to a relatively high non-ferritin bound iron pool 
in the white matter and in cortical layers IV/V. Oligodendrocyte differenti-
ation from oligodendrocyte precursor cells and myelin synthesis requires 
high iron concentrations, presumably because high amounts of enzymes 
with iron at their active sites are necessary (Todorich et al. 2009). The 
different labelling of plaques by the Meguro method and ferritin IHC is 
possibly caused by binding of iron to some of the many molecules other 
than ferritin in the extracellular compartment of plaques (Grundke-Iqbal 
et al. 1990; Connor et al. 1995). 
The specificity of the tested histochemical iron stains was checked by 
using sections depleted of iron in acid buffer as a negative control. The 
absence of iron staining in these iron-depleted sections confirms the re-
sults of another study using the Smith protocol on iron depleted sections 
(Smith et al., 2007). Staining of other metals in brain is not completely 
excluded by these experiments, but other studies report the absence of 
DAB oxidation in reaction products of ferrocyanide with copper, zinc or 
magnesium (Meguro et al., 2007; Meguro et al. 2003; Roschzttardtz et 
al. 2009). All this information supports that the modified, DAB enhanced 
Perl’s stainings used in this study are specific for iron ions.
Detailed knowledge of iron distribution in brain tissue may be of value for 
improving in vivo (MRI) diagnostics in AD and for a more complete picture 
of the pathogenesis of AD. In addition, it may also reflect normal brain 
ageing (Bartzokis et al. 2007b; Pfefferbaum et al. 2010) and the presence 
of other neurodegenerative diseases such as Parkinson’s disease (Loeffler 
et al. 1995; Brar et al. 2009), Lewy body disease (Tuite et al. 1996; Golts 
et al. 2002) and Huntington’s disease (Bartzokis et al. 2007a; Rosas et 
al. 2012). Although the present study was done on AD brain tissue, the 
results may be of use for the choice of iron stain in these other neurode-
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generative diseases.
In conclusion, the results of this study suggest that the Meguro method is 
the best technique to stain iron in 10-µm formalin fixed paraffin sections 
of human brain tissue. Ferritin IHC is a good alternative for demonstrat-
ing iron in microglia and, to a lesser amount, plaques, but somewhat less 
suitable for staining myelin-associated iron. 
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Abstract
Abnormal iron distribution in the isocortex is increasingly recognized as 
an in vivo marker for Alzheimer’s disease (AD). However, the contribution 
of iron accumulation to the AD pathology is still poorly understood. In 
this study, we investigated: 1) frontal cortical iron distribution in AD and 
normal aging and 2) the relation between iron distribution and degree of 
AD pathology. We used formalin-fixed paraffin-embedded frontal cortex 
from 10 AD patients, 10 elder, 10 middle aged, and 10 young controls and 
visualized iron with a modified Perl’s histochemical procedure. AD and el-
derly subjects were not different with respect to age and sex distribution. 
Iron distribution in the frontal cortex was not affected by normal aging but 
was clearly different between AD and controls. AD showed accumulation 
of iron in plaques, activated microglia, and, in the most severe cases, in 
the mid-cortical layers along myelinated fibres. The degree of altered iron 
accumulations was correlated to the amount of amyloid β plaques and tau 
pathology in the same block, as well as to Braak stage (p< 0.001).
AD and normal aging show different iron and myelin distribution in the 
frontal cortex. These changes appear to occur after the development of 
AD pathological hallmarks. These findings may help the interpretation of 
high resolution in vivo MRI and suggest the potential of using changes in 
iron-based MRI contrast to indirectly determine the degree of AD pathol-
ogy in the frontal cortex.
Keywords: Alzheimer’s disease, iron, myelin, magnetic resonance imaging
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Introduction
Future therapeutic interventions for Alzheimer’s disease (AD) require ear-
ly and preferably non-invasive clinical tests. A promising approach is in 
vivo detection of amyloid β (Aβ) plaques, neuropil threads (NT) and neu-
rofibrillary tangles (NFT), since these histological hallmarks of AD occur 
10-20 years before cognitive decline [1, 2]. In vivo visualization of Aβ 
plaque burden is already possible using positron emission tomography 
(PET) [3-6], but this technique requires the use of a radioactive tracer and 
a highly-specialized infrastructure. Recent advances in PET tracers for tau 
are promising to study the spatial and temporal relation between amyloid 
and tau accumulation in vivo. Nevertheless, our understanding of AD is 
incomplete, and the role of other modulators of the disease such as micro-
glia activation and iron accumulation is only partially understood. Recent-
ly, high field (7T) Magnetic Resonance Imaging (MRI) has been report-
ed to discriminate AD from control neocortex by changes in phase shift, 
which is a reliable indication of iron content in the brain [7, 8]. Other MRI 
studies show susceptibility induced changes in vivo in AD transgenic mice 
[9-11] and in postmortem human AD brain tissue [12, 13] that correlate 
to Aβ plaques histologically. Aβ plaques show iron accumulation [14-20] 
and it has been suggested that this iron causes the high T2* susceptibility 
effects [11, 21-23]. However, there may be additional pathological sub-
strates for iron-related MRI changes in AD. A subset of histological studies 
report iron accumulation in microglia in the cortex and hippocampus of 
AD patients [14, 16, 19]. In contrast, Smith et al shows iron accumu-
lation in NFT but explicitly report absence of iron labelling in glial cells 
[20]. AD-related iron accumulation in other tissue compartments than Aβ 
plaques is also suggested by the presence of diffuse MRI hypointensities 
in postmortem AD cortex [19, 24], but the pathologic substrate of these 
diffuse MRI hypointensities is not known. Moreover, we found a diffusely 
increased iron labelling in layers III-V of the frontal cortex of AD patients 
in a study comparing different histological iron stains [25].
The value of iron-based MRI changes for the diagnosis and staging of AD 
depends on an association between cortical iron accumulation and AD 
pathology. However, we are not aware of studies that have correlated the 
degree of cortical iron accumulation to Braak stage, local Aβ plaque load 
or local tau pathology. For the interpretation of iron-based cortical MRI 
changes as a biomarker for AD, it is also necessary to know the effect of 
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Table 1: Demographics and pathology of subjects. 
Abbreviations: M = male; F = female; AD = Alzheimer Disease; FE = iron, mcg = microglia; 
PLP = proteolipid protein.
Symbols: - = absent, + = mild, ++ = moderate, +++ = severe. See Methods for definitions.
aging on cortical iron accumulation. Aging itself leads to increased iron 
and ferritin concentrations in the cortex [26, 27], but the microscopically 
distribution of this age-related increase is unknown.
Our previous finding of increased cortical phase shift changes as a pos-
sible non-invasive clinical biomarker for AD [7] led us to investigate the 
following questions: 1) is the pathological substrate of iron based MRI 
changes in AD cortex limited to iron accumulation in Aβ plaques or is 
iron also accumulating in other tissue compartments? 2) Is cortical iron 
accumulation related  to Braak stage, local Aβ plaques and local tau pa-




We included autopsy material of 10 AD patients (age 65-90 years old, 5 
male and 5 female) with a clinical diagnosis of dementia and histological 
changes of at least Braak stage IV. Other neuropathological changes were 
absent, except for one patient with a 1 cm large meningioma in the pari-
etal lobe which had not been noticed during life. We also included autopsy 
material of 10 young (17-38 years old, 8 male, 2 female), 10 middle aged 
(51-57, 8 male, 2 female) and 10 old (74-89, 4 male, 6 female) con-
trols. No difference was found in sex distribution between the four groups 
(P>0.05). By definition, AD and old age controls were significantly older 
compared to the middle aged and young controls (P<0.05). The tissue 
was selected from the archive of the Department of Pathology, without 
knowledge of the degree of AD pathology in these blocks. All tissue sam-
ples were handled in a coded fashion, according to Dutch national ethical 
guidelines (Code for proper secondary use of human tissue, Dutch Feder-
ation of Medical Scientific Societies). Controls were included if the autopsy 
request file did not mention cognitive disorders, movement disorders, or 
extensive cerebrovascular disease. For all patients and controls, Braak 
stage was determined by two experienced neuropathologists (SGvD en 
RN) according to Alafuzoff [28] investigating the relevant brain areas. 
Patient characteristics, including Braak stage and additional neuropatho-
logical findings are presented in Table 1.
Tissue
Of each patient and control 1 block of formalin fixed paraffin embedded 
frontal cortex was taken. We choose the frontal cortex because increased 
diffuse iron in layers III-V was found earlier in a study designed to com-
pare different histological iron stains [25]. Tissue was fixed in standard 
formalin for a minimum of 1 week and a maximum of 6, on average 1-2 
weeks for both AD patients and controls. From each block, sequential 10-
µm thick sections were cut and stained consecutively for myelin - iron and 
Aβ- iron-tau. In addition, 20-µm thick sections were stained for iron par-
alleled by a 10-µm section of Aβ immunohistochemistry. The iron stained 
20-µm sections were used to count iron positive plaques (and in addition 
iron positive activated microglia) because at 20-µm the iron stain labelled 
much more plaques and labelled them more reproducibly. 
74
Figure 1: A: Each row represents consecutive sections of frontal cortex stained for iron, 
myelin (PLP immunohistochemistry) and Aβ immunohistochemistry. Controls show a similar 
iron distribution, irrespective of age, with increased amounts in the myelin rich areas: white 
matter and the inner and outer line of Baillarger (arrows). AD cortex (bottom row) shows a 
diffuse band shaped iron and PLP increase in cortical layer IV/V, extending to the inner part 
of layer III (arrow, and indicated by lines). 
B: higher magnification of A, Meguro iron stain. Controls show evenly distributed iron con-
centration in myelinated fibres and a good distinction between the lines of Baillarger. AD cor-
tex shows diffuse iron increase in the middle cortical layers (arrows), as well as iron positive 
plaques (asterisk), also concentrated in the middle cortical layers.
Histochemistry
Iron was detected using a modified diaminobenzidine (DAB)enhanced 
Perl’s protocol as described previously [22, 25]. Sections of 10 µm were 
incubated for 40 min in 1% potassium ferrocyanide (pH 1) and washed, 
followed by 75 minutes incubation with  methanol containing 0.01 M so-
dium azide (NaN3) and 0,3% H2O2. Then the sections were washed in 
0.1 M phosphate buffered saline (PBS), before visualization by 0.025% 
3,3’-diaminobenzidine (Sigma, St Louis, MO, USA) and 0.005% H2O2 in 
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0.1 M PBS for 40 min. The reaction was stopped by washing. For the 20 
µm sections incubation times were modified to: potassium ferrocyanide 
80 minutes, methanol-NaN3-H2O2 100 minutes and DAB 80 minutes. A 
slightly adapted protocol was used to compare the potential impact of 
using fixed versus fresh-frozen post-mortem tissue on the detection of 
iron. Frozen sections (20 μm) of the contralateral hemisphere of two AD 
patients were post fixed for 1 minute to prevent floating of the frozen sec-
tions from the slide during the staining procedure. The rest of the protocol 
was identical as described above apart from the 75 minutes incubation in 
methanol containing 0.01 M NaN3 and 0.3% H2O2: PBS was used instead 
of methanol.
Immunohistochemistry
Immunohistochemistry (IHC) was used to detect Aβ protein, hyperphosfo-
rylated tau, , proteolipid protein (PLP), myelin basic protein (MBP), mye-
lin oligodendrocyte glycoprotein (MOG) and HLA-DR. Specific information 
regarding the antibodies and the dilutions used can be found in Table  2. 
After de-paraffination, all 10 µm sections were blocked with methanol and 
H2O2 (0,3%) for 20 minutes at room temperature. Slides for Aβ IHC were 
pre-treated by 85% formic acid at room temperature for 1 hour, followed 
by 30 minutes in trypsin at 37°C. Pre-treatment for MBP and MOG was 
citrate buffer, pH 6, at boiling temperature for 20 minutes and cooling 
down for an hour. No pre-treatment was performed for tau and PLP IHC. 
All incubations with primary antibodies were overnight at room tempera-
ture. For Aβ, tau, PLP, MBP the second step was performed with rabbit anti 
mouse biotin (DAKO, dilution 1:200) for 1 hour at room temperature. For 
MOG swine anti-rabbit biotin was used (DAKO, dilution 1:600) for 1 hour 
at room temperature. The third step was performed by avidin biotin com-
plex (Vectastain, Vector, Burlingame CA, USA), according to the manufac-
turer’s instructions (incubation for 30 minutes at room temperature). DAB 
(0,05%) with H2O2 (0,005%) was used as a chromogen with an incuba-
tion time of 10 minutes at room temperature. Double labelling for ferritin 
and HLA-DR was performed by pre-treatment with boiled citrate buffer pH 
6.0 for 20 minutes and cooling down for one hour. Then, tissue was incu-
bated overnight with a 1:1 cocktail of the antibodies for ferritin and HLA-
DR (Table 2). The second step was performed by 2 hours incubation with 
a 1:1 cocktail of goat anti rabbit biotin (resulting dilution of 1:800) and 
goat-anti mouse alkaline phosphatase (resulting dilution 1:60), followed 
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Figure 2: A: iron accumulation in plaques (left) and microglia (middle) (both Meguro 
stain). On the right double labelling of iron positive cells by ferritin (brown) and MHCII 
(red).
B: band shaped increase of iron and PLP labelling in AD (right column) compared to an old 
control (left column). The right column illustrates that the normal distinction of the lines 
of Baillarger (arrow) is blurred by a band shaped iron/PLP increase in cortical layer IV/V 
extending to layer III (arrow heads). This is due to darker and thicker iron/PLP labelling of 
more crowded myelinated fibres (bottom panel).
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by 30 minutes incubation with avidin-biotin complex (Vectastain, Vector, 
Burlingame CA, USA), according to the manufacturer’s instructions. First, 
ferritin was visualized by 10 minutes incubation with DAB (0,05%) with 
H2O2 (0,005%) and 1% cobalt-chloride, followed by visualization of HLA-
DR by 25 minutes incubation with liquid permanent red (DAKO, 1:60), 
both at room temperature.
Semi-quantitative scoring of AD pathology and iron accumulation
Severity of the different pathological features in the frontal cortex was as-
sessed semi-quantitatively by an experienced neuropathologist (RN). Tau 
pathology was scored as: absent (-): no AT8 immunoreactivity,;mild (+): 
any AT8 immunoreactive structures up to occasional AT8 positive NT/NFT; 
moderate (++): microscopic diffuse AT8 positive NT up to visible cortical 
layer V; severe (+++): macroscopically visible layer V and other cortical 
layers, especially layers II/III.
Aβ pathology was scored as: absent (-): no Aβ plaques; mild (+): 1 Aβ 
plaque up to 10 fields with >50 plaques/ 100X field; moderate (++): >10 
fields of >50 plaques/100X field; severe (+++): all cortical areas show 
>100 plaques/100X field.
The degree of abnormal iron accumulation was scored by counting the 
amount of iron positive plaques and iron positive microglia with activated 
morphology outside plaques in the cortical 100X field with the highest 
density and by assessing the presence or absence of a band like increase 
of PLP and myelin associated iron labelling in cortical layers III-V. Scoring 
categories were defined as: absent (-): no plaque/microglial iron accu-
mulations; mild (+): 1-30 plaque/microglial iron accumulations; moder-
ate (++): 31-100 plaque/microglial iron accumulations; severe (+++): 
> 100 plaque/microglial iron accumulations. Abnormal iron accumulation 
in the cortex was scored as ++++ when the tissue showed a band of dif-
fusely increased PLP and iron in layer III–V in addition to > 100 plaque/
microglial iron accumulations 
Statistical methods
Age was compared between groups using a one-way ANOVA followed by 
a Bonferonni post hoc test. A chi-square test was used to compare sex 
distribution between groups. Semiquantitative iron score was correlated 
to Braak stage, and semiquantitative scores for Aβ plaques and tau pa-
thology by a linear by linear association test for ordinal variables [29]. 
All statistical analyses were performed using Statistical Package of Social 
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Figure 3: Semi-quantitative relation between iron accumulation and Braak stage 
(A), Aβ plaques (B) and tau pathology (C). Iron accumulation: 0: no iron accumu-
lation, 1: low, 2: intermediate and 3: high iron accumulation in plaques and micro-
glia, 4: high iron accumulation in plaques and microglia and a band shaped iron/
PLP increase in the middle cortical layers. For grading definitions see Methods. 
Sciences (SPSS, version 23; SPSS, Chicago, USA). A significant level of 
0.05 was used.
Results
Iron distribution in aging and AD
For histochemical visualization of iron, we used a modified Perl’s proce-
dure described by Meguro [22]. With this method, only non-heme iron is 
stained, mostly Fe3+ but also some Fe2+ [22]. Thus, if we refer to iron 
in this study, this is DAB enhanced Perl’s detectable iron meaning non-
heme iron, mostly Fe3+ and some Fe 2+. In the absence of Aβ plaques 
and tau pathology (20 out of 30 controls), iron distribution in the fron-
tal cortex was identical in young (9), middle aged (7), and old (4) con-
trols. These samples showed a finely diffuse, regular iron distribution with 
evenly increased density in myelin-rich areas: the white matter, the lines 
of Baillarger and the radially projecting thickly myelinated fibres from the 
white matter into the cortex (Fig. 1). 5 Controls (1 young, 2 middle aged 
and 2 old) had minimal Aβ plaques with or without minimal tau pathol-
ogy and showed the same iron distribution as controls without these AD 
lesions. The last 5 controls (1 middle aged, 4 old) showed variable iron 
accumulation in plaques and cells, directly correlating to the amount of Aβ 
plaques (Table 1). All 10 AD patients showed iron accumulation in plaques 
and cells (Table 1, Fig. 2A), most frequent in cortical layers III-V (Fig 1, 
bottom row). Intracellular iron was mainly localized in rounded microglia 
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with dilated cell-branches (Fig 2A), morphologically identified as activat-
ed microglia [30, 31]. Iron laden microglia were often seen in or directly 
around Aβ plaques but also apart from Aβ plaques. Iron accumulation 
was not observed in neurofibrillary tangles. In 3 out of 10 AD patients, we 
observed a diffuse band-shaped increase of both iron and PLP labelling in 
cortical layers IV/ V, and part of layer III, blurring the normal distinction 
between the lines of Baillarger (Fig. 1, 2B). At higher magnification, we 
observed darker and thicker labelling of neuropil fibres by iron and myelin 
proteins (PLP, MOG, and MBP) in a more crowded network (Fig. 2B). The 
band of increased mid-cortical iron and myelin labelling is not reflected by 
Aβ plaques, which are most dense in cortical layers I-IV.
Correlation between iron accumulation, myelin changes, plaques and tau 
pathology.
Iron accumulations were scored from 0-3 depending on the amount of iron 
positive plaques and microglia together (see “Materials and Methods”). 
In the presence of an increased iron band in the mid-cortical layers the 
degree of iron change was scored as 4. This histological iron score corre-
lated with Braak stage (P<0.001) and with the semi-quantitatively scored 
amount of Aβ plaques (P<0.001) and  degree of tau pathology (P<0.001). 
This level of statistical significance was the same for stratification by age 
as well as comparison of AD with the old age controls only (Fig. 3). Note 
that absence or low (score 0-1) iron accumulation in plaques and micro-
glia excluded advanced Braak stage, significant Aβ plaques or significant 
tau pathology. A band-shaped increase of diffuse iron and PLP/MBP/MOG 
labelling was only present in AD frontal cortex with the severest tau pa-
thology (Fig. 3 and 4), despite comparable amounts of Aβ plaques for all 
AD patients (Fig. 4, Table 1).   
Discussion
Technical Considerations
In the present study, we show non-heme iron accumulation in Aβ plaques 
and activated microglia in the frontal cortex of AD patients. This is in line 
with earlier studies showing iron in human Aβ plaques [17, 19, 20], and in 
activated microglia [14, 17, 30-33]. We did not identify iron accumulation 
in NFT or NT and this is in line with most [14, 17, 19], but not all [20], 
previous reports. The modified Perl’s protocol we employed was also used 
in other studies [17, 20] and principally stains Fe 3+ but also some  Fe 2+ 
80
Figure 4: Iron accumulation in AD, related to tau pathology and plaques. A: Both pa-
tients (first and second row) show similar amounts of plaques but only the tissue with the 
most severe tau pathology  shows a diffuse band shaped increase of iron/PLP labelling 
in the middle cortical layers (arrows). B: 20µm sections of the same blocks. Cortex with 
the most severe tau pathology shows more iron accumulation in plaques and microglia. 
[22, 34]. In addition to iron, other metals like copper, zinc, magnesium 
and aluminium have been shown in plaques and have also been implicat-
ed in AD  and plaque pathogenesis [18, 35-37]. Although the ferrocyanide 
that is applied in the Perl’s staining can also bind to other metals apart 
from iron, the precipitation of ferrocyanide with these metals does not ap-
pear to catalyze polymerization of DAB [22]. Indeed, ferrocyanide in com-
bination with DAB, detects iron with much higher sensitivity than copper, 
magnesium, zinc, or calcium [34]. This excludes a significant contribution 
of other metals to our visualization of iron in the tissue. 
Fixation and storage of tissue in formalin could lead to leakage of iron 
[38]. We took care not to include tissue that had been stored for prolonged 
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periods of time. Nevertheless, we investigated the potential impact using 
fixed versus fresh-frozen postmortem tissue of the same patients on the 
histochemical detection of iron. Briefly-fixed frozen sections qualitatively 
showed a similar band of increased iron staining as in the paraffin sec-
tions. Also, iron-laden plaques and microglia could be observed, but visual 
comparison showed that this was not more prominent than in the paraffin 
sections. Therefore, we conclude that a qualitative assessment of iron ac-
cumulation in different cell types is reliable in our selected samples.
Iron and Myelin
In addition to iron in Aβ plaques and microglia of AD cortex, we confirmed 
our preliminary observation [25] of a band-shaped increase of iron and 
PLP labelling in cortical layers III-V in a subset of AD patients with the 
most severe tau pathology, a finding we have not seen reported before. 
Figure 5: Schematic representation of the observed combinations of AD pathology and iron 
accumulation in frontal cortex. A: aging without plaques or tau pathology. B: controls with 
little diffuse plaques without iron accumulation. C and D: controls with increasing iron ac-
cumulation in plaques and microglia depending on the amount of plaques. E: AD with high 
Aβ plaque load and diffuse limited increase of tau pathology with increased iron accumu-
lation. F-H: Similar high plaque load with increasing tau pathology and iron accumulation. 
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This band reflected a more crowded network of neuropil fibres with thick-
er and darker staining for iron and several different myelin proteins. This 
finding is in line with a meta-analysis by Tao et al. [39] and a recent 
laser-ablation inductively coupled plasma-mass spectrometry imaging 
study [40], both showing increased iron levels in the cortex of AD pa-
tients compared to controls. Interestingly, the investigators also showed 
a trend of increased iron along white matter fibres, including myelinated 
fibres in the lines of Baillarger, in AD patients [40]. This is in line with our 
observations of increased iron along neuropil fibres in the mid cortical 
layers. This qualitative observation of increased myelin staining in a late 
stage of AD, a neurodegenerative disease, is counter-intuitive. This study 
was not designed to prove this observation quantitatively, and therefore 
we cannot exclude the possibility that atrophy or other disease-associ-
ated tissue changes may result in better antigen retrieval or compaction 
of myelinated fibres. Furthermore, increased labelling of myelin proteins 
does not prove an increased amount of functional myelin or myelinated 
fibres. However, we found a consistent increase of several myelin proteins 
by different anti bodies, making a true local myelin increase more likely. 
The mechanism by which severe AD may lead to increased cortical myelin 
proteins is open for speculation. Re-myelination is an almost default reac-
tion of the brain to demyelination caused by myelin damage and/or death 
of oligodendrocytes [41-44]. Thus, maybe the continuous severe tissue 
and cell damage in late stage AD leads to unbalanced de- and re-myeli-
nation. Indeed, myelin damage and restoration with increased oligoden-
drocyte proliferating cells (OPC) has been shown in an AD mouse model, 
although in the same study a decrease of OPC was found in the brains of 
human AD patients [45].  We observed a band shaped increase of iron/
myelin proteins in cortical layers III-V in a context of increased iron laden 
microglia. This is in line with the close relationship between iron and my-
elin synthesis extensively described in the literature [46, 47]. For exam-
ple, activated microglia have been described to drive the recruitment and 
proliferation of OPC and their differentiation to oligodendrocytes, as well 
as the formation of a myelin sheath around available axons [41, 42, 48]. 
Moreover, it is thought that microglia provide the high iron concentrations 
needed for myelinization and oligodendrocyte differentiation [47, 49, 50]. 
We observed increased labelling of myelin proteins as a late phenomenon, 
occurring only in cortices severely affected by both Aβ plaques and tau 
pathology. This does not support the hypothesis of an early role of myelin 
dyshomeostasis in the pathogenesis of AD [1]. However, disruption of 
83
cortical myelin may contribute to the ongoing neurological deterioration 
in late stage AD.
Iron and Microglia
In our cases, there was a clear presence of activated and iron laden mi-
croglial cells around Aβ plaques. The polarization of microglia, as in mac-
rophages, plays an important role in the neuroinflammatory response 
[51]. Classically activated, or M1, microglia drive the pro-inflammatory 
response, whereas the alternative activation state, or M2, is apparently 
an anti-inflammatory state, mediating tissue maintenance and repair. In 
macrophages, iron accumulation can directly activate the M1 phenotype. 
Conversely, M2-polarized cells are thought to be involved in iron recycling 
by expressing molecules involved in iron uptake and export [52]. Howev-
er, recent evidence shows that increased intracellular iron can alter micro-
glia polarization to a pro-inflammatory M1 phenotype [53].
Iron and Neurodegeneration
Iron accumulation is not merely a marker of neurodegeneration, but has 
been shown to play a crucial role in the progression of neurodegenera-
tion through several mechanisms [54-56]. Production of reactive oxygen 
species (ROS) leading to DNA damage and cell death is a well-known con-
sequence of iron overload and a common feature in many neurodegener-
ative diseases [56]. The mechanisms behind iron dyshomeostasis are still 
not fully understood, but several key processes in AD have been found to 
be of importance. Aβ processing and regulation of intracellular iron are 
e.g. both modulated by furin, thus mutually activating pro-amylogenic 
and intracellular iron accumulation pathways [57].
In addition, apart from driving the amyloid cascade, the intracellular com-
plexation of a certain iron species, magnetite, with Aβ appears to have an 
adverse effect on neuronal network function to a much larger extent than 
Aβ alone [54]. Also iron has been implicated in lipid metabolism through 
an interaction with Apolipoprotein E (ApoE); with the APOE-ε4 allele in-
ducing high levels of cerebrospinal fluid ferritin [58] and brain iron levels 
on MRI [55], possibly due to reduced clearance of iron because of the low 
affinity of APOE-ε4 to high-density lipoprotein [58]. As such, locally high 
iron concentrations in AD are likely the result of an intricate disbalance 
of iron uptake, mediated by furin and iron-regulating elements and iron 
clearance through microglial lysosomal degradation and ApoE-mediated 
transport [36, 59], see also further reviews on this topic. The fact that 
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transferrin and HFE mutations have a higher incidence in AD patients 
stresses the self-perpetuating loop caused by iron and amyloid deposi-
tion. In this context, a recent paper by Maher et al. raised the intriguing 
concept that iron deposition as an initiator of AD pathogenesis may not 
only be the result of iron-regulation gone haywire, but may also be caused 
by environmental factors such as airborne iron-bearing nanoparticles en-
tering the  brain through the olfactory bulb, [60]. In conclusion, at this 
moment it appears that iron toxicity in the brain is a complex phenome-
non, which may be both the cause and consequence of neurodegenerative 
processes. Further research should focus on the cellular localization of 
iron and its interaction with other mediators of AD, such as Aβ, as well as 
on the characterization of different iron species in the brain [61].
Iron and ageing
Some [27, 62] but not all [26] quantitative studies show increased frontal 
cortical iron concentrations with aging. The present study was not de-
signed to quantify iron load, but we found no changes in frontal cortical 
iron distribution from young to old controls without Aβ plaques. This sug-
gests that, although there may be increased iron load in aging cortex, the 
distribution of frontal cortical iron remains the same. This finding is help-
ful if iron based MRI changes may be used in the differentiation between 
an aging related disease like AD and aging.
Iron and APOE
APOE-ε4 is a well-known risk factor for AD and has recently been shown 
to correlate with ferritin levels in cerebrospinal fluid of APOE-ε4 carriers 
[58]. Van Bergen et al. (2016) demonstrated that magnetic suscepti-
bility, as measured with MRI, was significantly higher in APOE-ε4 carri-
ers with mild cognitive impairment (MCI) compared to MCI patients with 
other APOE variants [55]. These results confirm the hypothesis that the 
APOE-ε4 allele may increase the risk of developing AD via brain iron accu-
mulation. In our study, we unfortunately only had DNA available for 8/10 
of our AD patients, of which 2 were ε4/ε4, 5 were ε4/ε3 and only 1 ε3/
ε3. As expected, APOE-ε4 was highly prevalent in these patients and the 
APOE-ε3/ε3 patient showed frontal cortical iron accumulations similar to 
the others. However, our sample size was too small and thus our data do 
not allow any conclusion to be drawn about a relation between APOE sta-
tus and frontal cortical iron accumulations. Lastly, besides APOE status, 
mutations in some iron-regulating genes, such as HFE (hemochromato-
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sis), are also known to associate with age of onset in AD [63]. Future 
studies correlating iron-related genetic variants to brain iron accumula-
tion would be of interest.  
Iron and AD pathology
Finally, we showed a statistically significant correlation between iron ac-
cumulations (in Aβ plaques/microglia and myelinated fibres in the mid 
cortical layers) and the  amount of Aβ plaques and tau pathology, as well 
as between these iron accumulations and Braak stage. To our knowledge 
this is the first report that correlates frontal cortical iron accumulations 
with Braak stage and local tau pathology. This opens the possibility to 
grade the severity of AD pathology by MR in vivo. In Fig 5 we schematical-
ly represent the different combinations of AD pathology and pathological 
iron accumulations we encountered. These combinations suggest that his-
tochemically detectable iron accumulation is secondary to Aβ plaques and 
tau pathology and follows its progression. In controls, iron accumulation 
only occurs in the presence of Aβ plaques and the amount of iron accumu-
lation is correlated to the amount of Aβ plaques. For AD, Aβ plaque load 
does not increase much from Braak IV to VI, but iron accumulation and 
tau pathology both progress. The band shaped increase of diffuse iron-/
myelin protein labelling in cortical layers III-V especially appears to be a 
late phenomenon, occurring when several cortical layers, especially layer 
V and II/outer III are heavily involved by tau pathology. 
Conclusion
The presented data show a correlation between frontal cortical iron accu-
mulation and AD pathology independent of age. Iron is not only accumu-
lated in Aβ plaques but also in activated microglia and in myelinated fibres 
in the middle cortical layers with increased labelling of myelin proteins. 
Ex vivo MRI has shown iron related hypointensities in iron rich cortical 
myelin tracts and iron accumulation in microglia and Aβ plaques [13, 64, 
65], suggesting the potential to detect these iron rich cortical areas with 
in vivo MRI. Complementary work from our lab showed that changes in 
iron and in myelin organization co-localize on a pixel-by-pixel basis to MRI 
contrast changes, demonstrating that iron is a major source of cortical 
MRI contrast in AD (data submitted for publication). The direct clinical 
relevance of these findings is supported by an earlier study in which high 
field susceptibility-weighted MR already demonstrated that iron-related 
MR contrast was detectable in human subjects, and shows different con-
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trast between controls, patients with cognitive impairment and patients 
with clinically diagnosed AD [7]. Thus, iron imaging with MR reflects mul-
tiple aspects of AD pathology beyond Aβ plaques and therefore offers 
complementary in vivo imaging possibilities beyond PiB-PET amyloid and 
tau-PET imaging. 
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Abstract 
Non-invasive methods to detect Alzheimer’s disease (AD) in vivo at an 
early stage are important to increase our still-incomplete understanding 
of the pathophysiology of the disease. In this study we assessed whether 
differences in cortical appearance could be observed in AD patients us-
ing 7T magnetic resonance imaging in vivo and to assess the nature of 
these changes by a histological-radiological correlation ex vivo. In vivo 
regional cortical differences between probable AD patients (n=14, mean 
age 76.4 years (range: 68 - 86), 9 males) and healthy control subjects 
(n=15, mean age 75.1 years (range: 69 – 80), 10 males), visible on 7T 
susceptibility-weighted images, were analyzed after defining a novel scor-
ing method based on the cortical appearance. In addition, postmortem 
magnetic resonance imaging of confirmed AD cases (n=6) was performed 
to assess the histological correlates of the changes observed in vivo in AD 
patients. A chi-square test showed that diffuse hypointense bands were 
frequently found in the cortex of the frontal lobes of AD patients (57%), 
but not in controls, p = 0.001. Histologic correlation revealed that the 
pattern of the susceptibility-weighted contrast in the cortex of AD patients 
does not primarily co-localize with amyloid plaques or neurofibrillary tan-
gles, but with microglia- and myelin-associated iron accumulation and 
with an altered myelin cytoarchitecture. Our observation of disturbed iron 
accumulation and myelin architecture in AD has important implications for 
the understanding of the pathophysiological mechanisms underlying this 
disease, and also for in vivo diagnosis of AD.
Keywords: Alzheimer’s disease, cortex, beta-amyloid, magnetic reso-
nance imaging, iron.
Abbreviations: amyloid-beta (Aβ), diaminobenzidine-tetrahydrochloride 
(DAB), echo time (TE), electron microscopy (EM), gray matter (GM), Mini 
Mental State Examination (MMSE), National Institute of Neurological and 
Communicative Disorders and Stroke and Alzheimer’s disease and Re-
lated Disorders Association (NINCDS-ADRDA), paired helical filament-tau 
(AT8), protolipid-protein (PLP), repetition time (TR), susceptibility-weight-
ed (SW), white matter (WM).  
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Introduction
For the definitive diagnosis of Alzheimer’s disease (AD) histological post-
mortem detection of amyloid plaques and neurofibrillary tangles is re-
quired. During life, only a probable diagnosis can be made that is based 
primarily on clinical signs and symptoms (Montine et al., 2012). However, 
recently it has been proposed to use biomarkers based on CSF analysis, 
structural MRI and amyloid imaging using PET, as supporting diagnostic 
criteria in research settings (Jack, Jr. et al., 2010). 
Over the past few years, the feasibility of detecting the histological hall-
marks of AD using MRI has been explored by many research groups. 
In general these efforts have focused on detecting individual amyloid 
plaques: increased iron accumulation around amyloid plaques induces 
a magnetic susceptibility effect, which is visible as hypointense foci on 
T2*-weighted or susceptibility-weighted (SW) MRI in the cerebral cortex 
of transgenic AD mouse models and in human post-mortem brain slic-
es (van Rooden et al., 2009; Meadowcroft et al., 2009; Chamberlain et 
al., 2011). However, these findings have not yet been convincingly rep-
licated in vivo in patients, and it is doubtful whether detecting individual 
amyloid plaques with MRI will be possible in a clinical setting given the 
required high anatomical resolution, limited scanning time, and physio-
logical motion of the patient. Furthermore, the central role of amyloid in 
the pathophysiology of AD remains a topic of debate. Although amyloid is 
still considered to be a hallmark as well as an initiating factor in the pro-
gression of the disease, there is increasing evidence that other primary 
or interacting causes, including changes in iron metabolism, may exist 
(Karran et al., 2011; Fjell and Walhovd, 2012).
Recent advances in human MRI systems operating at an ultra-high mag-
netic field strength (7 Tesla and higher) show that the increased sensitiv-
ity to susceptibility effects generates iron-based contrasts in the human 
brain that have not been observed at lower fields (Fukunaga et al., 2010). 
The aim of our study was to establish whether 7T MRI allows in vivo de-
tection of differences in the cerebral cortex between probable Alzheimer’s 
disease patients and healthy age-matched controls. Having observed a 
difference, we then determined the histological substrate of the chang-
es by comparing MRI to light- and electron microscopy (EM) of human 
post-mortem material of Alzheimer’s disease patients and controls. 
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Table 1: Characteristics of patients and controls and scoring results of 
in vivo the SW imaging study 
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Materials and Methods 
A. In vivo MRI study:
Participants
This study was approved by the institutional review board. In all cases, 
informed consent was obtained according to the declaration of Helsinki. 
Fourteen probable AD patients (mean age 76.4 years (range: 68 - 86), 
9 males) and fifteen control subjects (mean age 75.1 years (range: 69 – 
80), 10 males) were included (table 1). Alzheimer’s disease patients were 
recruited from the memory outpatient clinic of our institution. Memory 
outpatient clinic patients were referred to the hospital by their general 
practitioner or a medical specialist. Prior to the 7T MRI study these pa-
tients all underwent a routine clinical protocol, comprising a whole brain 
MRI (performed on a clinical 3 Tesla platform), a battery of neuropsycho-
logical tests, and a general medical and neurological examination per-
formed by a neurologist, psychiatrist or internist-geriatrician. The diagno-
sis was made in a multidisciplinary consensus meeting using the National 
Institute of Neurological and Communicative Disorders and Stroke and AD 
and Related Disorders Association (NINCDS-ADRDA) criteria for diagnos-
ing probable AD (McKhann et al., 1984). Participants with the diagnosis 
‘probable Alzheimer’s disease’, who were capable of giving informed con-
sent and who had a Mini Mental State Examination (MMSE) of ≥19 were 
selected for inclusion in the 7T study, either retrospectively within one 
year after attending the memory clinic, or prospectively. Healthy control 
subjects were recruited by focused advertisements. Subjects between 69 
and 80 years of age, who were living independently and had an MMSE of 
≥25 and a Geriatric Depression Scale (GDS) of ≤4 were selected for inclu-
sion. Control subjects with the following diseases were excluded: stroke, 
Parkinson’s disease, diabetes mellitus, rheumatoid arthritis, polymyalgia 
rheumatica, cancer, heart failure, and chronic obstructive pulmonary dis-
ease. 
MRI data acquisition
Our study was performed on a human whole-body MRI system operating 
at a magnetic field strength of 7 Tesla (Philips Healthcare, Best, The Neth-
erlands) using a quadrature transmit and 16-channel receive head coil 
(Nova Medical, Wilmington, MA, USA). Alzheimer’s disease-related pa-
thology spreads throughout almost the entire brain, but macroscopically 
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Table 2: Post-mortem subject characteristics and SW imaging analysis.
typically involves the fronto-temporal association cortices (Duyckaerts et 
al., 2009; Bartzokis, 2011; Alves et al., 2012). Participants were scanned 
using a 2D flow-compensated axial T2*-weighted gradient-echo sequence 
which included the frontal lobe for detection of Alzheimer’s disease pa-
thology with a total imaging duration of 10 minutes. Imaging parameters 
were: repetition time (TR)/echo time (TE) 794/25 ms, flip angle 45°, slice 
thickness 1.0 mm with a 0.1 mm interslice gap, 20 slices, 240 x 180 x 22 
mm field of view, 1024x768 matrix size – resulting in an in-plane spatial 
resolution of 0.24 x 0.24 mm2. The bandwidth per pixel was 46 Hz, cor-
responding to a readout length of approximately 22 ms. Frequency and 
phase encoding directions were along the anterior-posterior and right-
left axes, respectively. This sequence is very sensitive to image artifacts 
arising from resonance frequency fluctuations within the brain caused by 
slight patient movements, even in areas significantly away from the head, 
and so a navigator echo was included to correct for these artifacts.(Ver-
sluis et al., 2010) Shimming up to third order was performed using an 
image based shimming approach (Schar et al., 2004). Phase images were 
unwrapped by high-pass filtering with a 92x92 kernel size. SW images 
were constructed by applying four phase mask multiplications (Haacke et 
al., 2004).
Whole brain imaging at this high spatial resolution (0.24 x 0.24 x 1 mm3) 
however would result in an impractically long imaging duration, particu-
larly for Alzheimer’s disease patients (Versluis et al., 2010). Since suscep-
tibility artifacts induced by the temporal bone hampered the imaging of 
the temporal lobe, the final imaging volume focused on the frontal lobe, 
which is less prone to atrophy than the temporal lobe, but is known to 
accumulate high amyloid loads (Rowe and Villemagne, 2011), to have 
a lower metabolic rate (Langbaum et al., 2009), and to have an altered 
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resting state network connectivity in Alzheimer’s disease(Rombouts et al., 
2005).
Image analysis
Based on previous 7T MRI studies of the human cortex in post-mortem 
brain specimens of Alzheimer’s disease patients (van Rooden et al., 2009) 
and in vivo imaging of healthy volunteers (Duyn et al., 2007) we devel-
oped a scoring method to capture the appearance of the cortex on SW 
images. We defined a normal cortex based on the following criteria: a) 
a cortical ribbon containing one homogeneous layer with a higher signal 
intensity as compared to the adjacent white matter (WM), b) a cortical 
ribbon containing two well-defined, homogeneous layers, with the su-
perficial layer demonstrating a higher signal intensity compared to the 
deepest layer (the layer adjacent to the WM) and the WM, or c) a cortical 
ribbon with three layers: the same layers as previously described sepa-
rated by a third thin layer with a lower signal intensity than the other two 
layers (fig. 1). Abnormal cortex was classified as a deviation from the 
normal patterns described above, showing the presence of well-defined 
foci of signal loss (hypointense foci) and/or more diffuse areas with lower 
signal intensity in the superficial layer as compared to the adjacent WM 
(a diffuse band) (fig. 1). Features were scored as present or absent per 
subject in several predefined gyri of the frontal lobe (table 1). Uniform 
window settings were used for all images. Images were scored by two 
neuroradiologists (B.E. and M.L.) who were blinded for the diagnosis in a 
consensus reading.
Statistics
A Mann-Whitney U-test was used to assess differences in age and MMSE, 
and a chi-square test was used to assess differences in gender between 
Alzheimer’s disease and control groups. For each feature (hypointense 
foci and/or a diffuse band), a Fisher’s exact test was performed per brain 
region. Positive and negative predictive values of the features to detect 
Alzheimer’s disease were calculated per brain region. All statistical analy-
ses were performed with the Statistical Package of Social Sciences (SPSS 
17.0.1; SPSS, Chicago, Ill).
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Figure 1: The observed variations of in vivo 7T SW imaging appearance of the human cortex 
Shown are the middle/inferior frontal brain area of an Alzheimer’s disease patient (A) and 
healthy elderly controls (B, C, D). An clear example of a cortical ribbon containing a hy-
pointense diffuse band is observed in the Alzheimer’s disease patient (A). Please note the 
blurring of the edges of the layers. (B) shows an example of a cortical ribbon containing 
one regular layer with higher signal intensity than the adjacent WM. In (C) a cortical ribbon 
is shown containing two well-defined layers. (D) shows a cortical ribbon containing three 
well-defined layers.
B. Post-mortem MRI study:
Study design
To investigate the histological substrates responsible for the observed in 
vivo MRI changes at 7T, we applied similar scan methods on postmor-
tem material of Alzheimer’s disease patients and controls using a ver-
tical-bore 9.4 T system (Bruker Biospin, Ettlingen, Germany). For each 
sample high-resolution (isotropic 40 µm voxels) images were acquired, as 
well as images with a similar resolution (isotropic 200 µm voxels) as were 
used in the in vivo study. The lower resolution MR images were acquired 
to help the translation between the in vivo and ex vivo MR data sets. The 
high-resolution MR images helped to identify the particular MR images 
that matched best with the 8-µm thick histological sections.
Sample preparation
Brain tissue was obtained from the tissue bank of the Department of Pa-
thology at our institution and from the Netherlands Brain Bank (NBB, Neth-
erlands Institute for Neuroscience, Amsterdam). Following a post-mortem 
interval of <19 hours, brains were resected and stored in 4% paraform-
aldehyde. At both institutions brain tissue was examined histologically 
for the presence of Alzheimer’s disease-related pathology and scored us-
ing the Braak classification (Braak et al., 2006). Based on availability 6 
samples with a clinical diagnosis of Alzheimer’s disease by histological 
confirmation were selected, as well as 3 age-matched non-demented con-
trols (table 2). Patient anonymity was strictly maintained. All tissue sam-
ples were handled in a coded fashion, according to Dutch national ethical 
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Figure 2. In vivo cortical differences seen on SW images in Alzheimer’s disease patients ver-
sus age-matched control subjects  Regional distribution of the observed variations of in vivo 
7T SW imaging appearance as presented in fig. 1, shown in an Alzheimer’s disease patient 
and a control subject. The left two columns (A and C) show an Alzheimer’s disease patient 
and the right two columns (B and D) a control subject. The upper row (A and B) shows the 
superior frontal region, the lower row (C and D) the middle and inferior frontal region. In the 
Alzheimer’s disease patient a diffuse band is seen in both regions of the frontal lobe and the 
double arrows show several locations containing this band whereas in the control subject 
this diffuse band is absent and a regular layer (arrow), two-well defined layers (arrowhead) 
and three-well defined layers (small arrow) could be detected.
guidelines (Code for Proper Secondary Use of Human Tissue, Dutch Fed-
eration of Medical Scientific Societies). To avoid formalin-induced artifacts 
in the MR images only material fixed for a period of between 3 months 
and 2 years was used (van Duijn et al., 2011). From each subject 1 tissue 
block of approximately 4 x 15 x 15 mm3 was resected from the medial 
temporal lobe using a vibratome (VT1000S, Leica, Germany). Care was 
taken to ensure that the samples were resected with a similar gyral ori-
entation. Residual formalin was washed out by placing the samples in 
phosphate buffered saline (PBS) for >24 hours to partially restore MR 
relaxation parameters (Shepherd et al., 2009). For MRI, each sample was 
placed in a customized tissue container and immersed in a proton-free 
fluid (Fomblin LC08, Solvay). Air was removed by application of a vacuum 
for several minutes (van Duijn et al., 2011).
Post-mortem MRI
Scans were acquired on a 9.4 Tesla vertical bore MRI system, equipped 
with a 1 T/m actively-shielded gradient insert and Paravision 5.0 imaging 
software (Bruker Biospin, Ettlingen, Germany). A 20-mm diameter bird-
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cage transmit/receive coil was used to acquire T2*-weighted 3D gradient 
echo images with TR = 75 ms; TE = 22.5 ms; flip angle = 25° at either 
200 μm isotropic resolution with 20 signal averages, or 40 µm isotropic 
resolution with 28 signal averages. The average scan time per resolution 
was approximately 40 minutes (200 µm resolution) or 25 hours (40 µm 
resolution), with minor differences between samples of slightly different 
sizes. To create SW images comparable to in vivo scans, the 200 µm 
resolution phase images were unwrapped using a k-space Hanning filter 
with a width set to 50% of the image size (Wang et al., 2000). Final SW 
images were reconstructed from the original images by four phase mask 
multiplications (Haacke et al., 2004). All data processing was performed 
with MatLab (MathWorks, Natick, MA).
Postmortem image analysis
For assessment of ex vivo SW images we used the same criteria as were 
used in vivo for defining normal and abnormal cortex (hypointense bands 
and hypointense foci). In addition, since the ex vivo images showed in-
creased anatomical detail compared to the in vivo scans (due to the ab-
sence of physiological motion), a third category of abnormal cortex could 
be added, namely diffuse areas with low signal intensity, not extending 
parallel to the cortical surface (as in healthy tissue) but instead expanding 
locally in an irregular fashion throughout the cortex, a feature which we 
have termed “clouds”. Window settings were optimized for each sample 
based on the WM and gray matter (GM) histogram. The 200 μm SW im-
ages were scored blinded for diagnosis by a neuroradiologist (M.v.B) and 
MR-microscopy expert (L.v.d.W) in a consensus reading.
Histology and electron microscopy
All brain samples were paraffin-embedded and serially cut into 8-µm thick 
sections. Tissue morphology was assessed by standard hematoxylin-eosin 
(HE) staining. Iron was detected using a 3’3-diaminobenzidine-tetrahy-
drochloride (DAB) enhanced Perls’ staining protocol for light microscopy 
and EM which has shown to be the most sensitive to detect iron-positive 
structures in paraffin-embedded human AD brain tissue (Meguro et al., 
2007; van Duijn et al., 2013). Consecutive sections were (co-)stained 
for amyloid-beta (Aβ), paired helical filament-tau (AT8), myelin (protolip-
id-protein (PLP)), microglia (CD68 and HLA-DR) and activated astrocytes 
(GFAP) (Supplementary table 1). Endogenous peroxidase was blocked 
by 30 minutes of incubation in methanol with 0.02% H2O2. After these 
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Figure 3. Comparison 
of post-mortem SW im-
ages with histology
The SW image of the Alzheim-
er’s disease patient (table 2 
subject 7) showed a midcorti-
cal hypointense band (yellow 
arrows) in addition to several 
focal hypointensities, as op-
posed to a clear homogeneous 
cortex as seen in the control 
subject (table 2 subject 1). 
For detailed evaluation similar 
regions of interest of the cor-
tex are shown alongside each 
corresponding main image 
and the cortical layers have 
been assigned accordingly. 
Neither the cortical distribu-
tion of Aβ or tau matched the 
hypointense band. Tau typi-
cally showed a band-like pat-
tern in cortical layers II – III 
and V, and so is not co-local-
ized in the layer correspond-
ing to MR signal decrease. 
Both iron and myelin correlat-
ed with the observed pattern 
of band-like hypointensities, 
including a diminished stain-
ing in the inner cortical lay-
ers V and VI. As compared to 
the control, the iron staining 
of the Alzheimer’s disease 
subject showed an increase 
in cellular deposits and dif-
fuse iron within the neuropil, 
mainly centred around cortical layer IV spreading to both sides with overlap in layers III and 
IV. The myelin distribution visualized by the PLP-immunostaining showed a similar pattern of 
increased staining in the Alzheimer’s disease subject resulting from a denser network of thin 
myelinated fibres. Similar to previous reports, in the Alzheimer’s disease patient the cor-
tex also contained several small roundish areas devoid of myelinated fibres suggesting the 
presence of amyloid plaques based on their morphological appearance (Mitew et al., 2010.)
pre-treatments, non-specific binding was minimized by incubation with 
10% fetal calf serum (DakoCytomation). Labelling was visualized by DAB 
staining (DakoCytomation). All sections were digitized with a microscope 
scanner (Panoramic, 3DHistotech, Hungary) for global and microscopic 
evaluation. To assess co-localization of cellular iron with CD68, HLA-DR 
or GFAP-positive cells, sections stained for iron as described above were 
subsequently treated according to the previously described immunohis-
tochemical procedures except for using an Alexa647-labeled secondary 
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Figure 4. Characterization of intracortical iron 
distribution in Alzheimer’s disease brain tissue 
Shown are the different types of cellular and neu-
ropilar intracortical iron in the medial temporal lobe 
of an Alzheimer’s disease patient (table 2 subject 
7). (A) Indicated by the brown colour due to the 
modified 3’3-DAB enhanced Perls’ iron staining, iron 
is present as perinuclear (arrow head) and stellate 
cellular deposits (arrow), and as diffuse iron spread 
throughout the neuropil (asterix). Morphologically 
the cellular iron was attributed to oligodendrocyte 
or microglia cells. The latter was further verified 
by the co-localization of iron (black) with (B) CD68 
(red) and (C) HLA-DR (red) immunostaining. As in-
dicated by both stainings, even in close proximity 
to these iron-bearing microglia, several microglia 
were present that were completely devoid of iron. 
(D) Ultrastructurally, as shown by EM, neuropil iron 
was found to be located in the myelin sheets folded 
around an axon. (E) A example of iron found as-
sociated with an amyloid plaque. (F) The negative 
iron staining of a consecutive section did not result 
in any DAB enhancement, thereby confirming spec-
ificity of the iron stain (axon, ax; myelin sheet, my)
anti-mouse antibody for immunofluorescence. Co-localization of these an-
tigens with iron was assessed using a confocal fluorescence microscope 
(LSM 510, Zeiss, Germany). Iron-stained ultrathin (100 nm) sections 
were examined by electron microscopy (JEM-1011, JEOL, Germany) to 
assess the exact localization of the cortical iron in the neuropil. 
Histology-MRI correlation
The digitized histological sections were matched with their corresponding 
high-resolution (40 µm) MR images by visual comparison of the contour 
and vascular architecture of each section. The corresponding low-reso-
lution SW image that matched best with the histological section could 
then be identified directly since the two SW image datasets are inherently 
co-registered. To assess the histological substrate of the cortical chang-
es observed on MR images, the digitized histological sections were first 
inspected at low magnification (2x) alongside the corresponding low-res-
olution SW image. Subsequently, these areas were further analyzed mi-
croscopically at higher magnification (40x) to look for the microscopic 
changes underlying the MR. All observations were independently verified 
by three neuropathologists (R.N., S.v.D., M.F.). 
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Results
The characteristics of the participants for in vivo MRI are shown in table 
1. No difference in age (p = 0.497) or gender (p = 0.893) was found be-
tween patient and control groups. Scores for global cognitive functioning 
(MMSE score) were significantly higher in controls (29.2 points; range 
27-30) than in patients with Alzheimer’s disease (22.5 points, range 19-
26), p<0.001. 7T SW images of the frontal lobe of probable Alzheimer’s 
disease patients (n=14) were visually compared to those of control sub-
jects (n=15).
We developed a scoring method to rate the cortical appearance based on 
previous 7T observations in normal brain and postmortem observations 
in Alzheimer’s disease patients, distinguishing normal-appearing cortical 
patterns with one or more homogeneous layers from hypointense foci 
or hypointense diffuse bands (fig. 1). Clear in vivo differences between 
Alzheimer’s disease patients and controls were seen in terms of the pres-
ence of diffuse hypointense bands on the SW images (table 1, fig. 2). 
Within the frontal lobe, these patterns were found in the middle and infe-
rior frontal gyri in eight out of 14 patients, whereas these diffuse bands 
were not observed in any of the control subjects. In these frontal gyri, the 
diffuse hypointense band was significantly more prevalent in Alzheimer’s 
disease patients as compared to controls (p = 0.001), with positive pre-
dictive and negative values of 100% and 71%, respectively. In the superi-
or frontal gyrus, a similar hypointense band was observed in only two out 
of the 14 Alzheimer’s disease patients and in none of the control subjects: 
there was no significant difference between the two groups (p = 0.224). 
For this specific cortical region, corresponding positive and negative pre-
dictive values were 100% and 55%, respectively. Foci of signal loss were 
not observed in the frontal lobe in either Alzheimer’s disease patients or 
control subjects.
Post-mortem cerebral cortex samples of six Alzheimer’s disease cases and 
three age-matched controls were scanned with a similar SWI protocol as 
for the in vivo MRI. Two of the controls showed a normal cortex. The con-
trol subject with an abnormal cortex revealed Alzheimer’s disease-type 
pathology (Braak stage III), despite the absence of an ante-mortem clini-
cal Alzheimer’s disease diagnosis. We therefore discuss the findings in this 
case separately. 
In all postmortem AD samples (6 out of 6), an abnormal cortex was ob-
served on SW images (table 2). Hypointense bands were observed in five 
out of six AD cases, and in the control with Braak III. Due to the lack of 
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Figure 5. Structural altera-
tions of intracortical myelin
In addition to the observed differences 
in myelin highlighted by fig. 3, this fig-
ure presents a more detailed compari-
son of the intracortical myelin of the 
medial temporal lobe of (A) an Alzheim-
er’s disease patient (table 2 subject 4) 
and (B) a non-demented age-matched 
control (table 2 subject 1). Shown are 
midcortical regions (layer IV) with a 
comparable orientation assessed by a 
PLP-immunostaining (brown). At this 
higher magnification, the intracortical 
myelin in the Alzheimer’s disease sub-
jects was characterized by an accen-
tuated PLP staining due to changes in 
myelin structure comprising fragmen-
tation, increased segmental tortuos-
ity and bead-like varicosities. As a re-
sult the PLP staining of the Alzheimer’s 
disease cortex appeared disorganized 
with loss of individually discernable fi-
bres and orientation when compared 
to the cortex of the control subjects.
physiological movements, the ex vivo images that were acquired with a 
similar resolution as the in vivo images provided more anatomical de-
tail, and demonstrated that the hypointense bands did not cover the full 
width of the cortex, but were located centrally in the cortex (fig. 3). Hy-
pointense foci were observed in 2 out of 6 AD cases, and in the 1 control 
specimen with Braak III. In addition to the scoring criteria defined for the 
in vivo scans, in these post-mortem samples a third category of cortical 
disturbance could be observed, consisting of cloud-like areas of low signal 
intensity with less alignment along, and more expansion through, the cor-
tical layers (4 out of 6 AD cases, and in the control subject with Braak III). 
Comparing radiological and histological data of the same sample, the ep-
icentre of the hypointense bands and clouds observed on the ex vivo MR 
images could be localized in cortical layer IV. Subsequently, we assessed 
which of the histological markers (Aβ, tau, iron, and myelin) showed a 
similar distribution over the cortical layers to the hypointense bands and 
clouds. We observed that the hypointense bands and clouds on MRI co-lo-
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calized with areas characterized by an increased presence of iron and 
changes in myelin structure (fig. 3). Only cortices that were scored as 
abnormal on SW images demonstrated these accentuated local patterns 
for iron and myelin on histological examination. Interestingly, no co-local-
ization was observed between the hypointense bands and clouds on MRI 
and areas staining for Aβ or tau. Tau pathology typically affected cortical 
layers II – III and V. Aβ staining was present to an equal extent across 
all cortical layers. Microscopically, some of the hypointense foci observed 
on the ex vivo images corresponded to large amyloid plaques, but these 
focal signal voids barely contributed to the observed hypointense cortical 
bands. 
Since the pattern of the abnormalities observed on MRI corresponded 
best with the patterns observed on iron and myelin-stained tissue, we 
examined these stainings in more detail. Microscopically, using higher 
magnification, four different types of iron accumulation were observed 
in the cortex: 1) diffuse neuropil deposition associated with myelinated 
fibres, 2) dense stellate cytoplasmic iron accumulation in microglial cells, 
3) a dense thin line of perinuclear iron accumulation in oligodendroglial 
and microglial cells, and 4) iron associated with amyloid plaques (fig. 4). 
All 4 types of iron deposits were more abundant in the subjects with an 
abnormally appearing cortex on postmortem MRI, including the control 
subject with Braak III. The first 3 types of iron deposits were localized 
differently in the cortical layers: neuropil iron accumulation was centered 
in layer IV, extending into layers III and V of the cortex; stellate glial ag-
gregates were most abundant in the middle cortical layers (layers III and 
IV), but were also present to a lesser extent in the deep cortical layers 
(layers V and VI), and perinuclear glial iron accumulation was most abun-
dant in layers V and VI, followed by layers IV and III (fig. 3). In addition, 
increased microglial and neuropil iron accumulations were also observed 
in areas characterized by cloud-like hypointensities on MRI. EM analysis 
revealed that the diffuse iron in the neuropil was located predominantly in 
oligodendrocytic myelin sheaths (fig. 4D).
The association of iron with myelin sheaths in the neuropil led us to exam-
ine the cortical myelin in more detail using a PLP staining. Interestingly, 
the intensity of myelin staining also showed a colocalization with the low 
signal intensity bands and clouds on MRI (fig. 3). Histologically, these 
areas were characterized by an accentuated PLP staining due to changes 
in myelin structure comprising fragmentation, increased segmental tortu-
osity and bead-like varicosities, centralized in layer IV, but extending to 
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layers III and V in the AD patients (fig. 3 and 5). Furthermore, as expect-
ed, small round plaque-like areas that were devoid of any myelin fibres 
were observed in cortical areas containing a high number of Aβ deposits.
 
Discussion
Using 7T MRI we observed striking differences in vivo in the frontal cortex 
between AD patients and age-matched controls. In patients with probable 
AD we found a disturbance of the layered structure of the cortex. Previous 
studies in healthy subjects demonstrated that cortical lamination at 7T re-
flects intracortical myeloarchitecture (Duyn et al., 2007; Fukunaga et al., 
2010; Cohen-Adad et al., 2012), and this normal pattern of cortical lami-
nation was attributed to differences in myelin-associated iron and myelin 
lipids in the different cortical layers (Duyn et al., 2007). Our current study 
shows that in AD patients the cortical areas of altered SW contrast co-lo-
calize with areas of increased microglia- and myelin-associated iron accu-
mulation and also with changes in myelin cytoarchitecture. However, our 
data also demonstrate that the pattern of the changes observed on MRI 
does not correspond to the pattern of amyloid deposits. These observa-
tions are not in line with the previous assumption, mostly based on animal 
experiments, that T2*-weighted and SW imaging contrast in Alzheimer’s 
disease primarily reflects the presence of iron associated with amyloid 
plaques (Duyn et al., 2007; van Rooden et al., 2009; Meadowcroft et al., 
2009; Chamberlain et al., 2011). Our observations of disturbed iron accu-
mulation and myelin architecture have important implications for in vivo 
diagnosis of AD, and also for the understanding of the pathophysiological 
mechanisms underlying this disease.
According to the amyloid hypothesis oligomeric forms of Aβ are the trig-
ger for a cascade of events that ultimately results in dementia. However, 
there is increasing evidence that a range of other ethological factors have 
an important impact on this cascade, presumably by interacting with the 
Aβ aggregates or by subsequent cellular changes which follow it (Herrup, 
2010; Bartzokis, 2011; Fjell and Walhovd, 2012). In our study, we found a 
close correlation between SW MRI contrast changes, myelin changes and 
increased iron accumulation in cortices with Alzheimer’s disease patholo-
gy. Interestingly, changes in iron metabolism and myelin breakdown have 
both been mentioned as potential upstream mechanisms for Alzheimer’s 
disease (Herrup, 2010; Bartzokis, 2011). 
Iron and myelin are closely associated in the brain. Seventy percent of 
the brain’s iron is located in oligodendrocytes. Maturation of oligodendro-
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cytes and myelin synthesis are both dependent on the availability of iron 
(Todorich et al., 2009; Bartzokis, 2011). During demyelination processes 
in disease, as well as during normal myelin turnover, iron is assumed to 
be released from myelin into the brain tissue (Bartzokis, 2011), Our ob-
servation of increased iron in microglial cells (which have an important 
phagocytic role) in areas of altered myelin structure suggests that the 
observed MRI changes are a reflection of increased demyelination. 
Cortical demyelination has been observed previously in AD, but mainly 
as areas of focal myelin loss in the immediate vicinity of amyloid plaques 
(Mitew et al., 2010; Serrano-Pozo et al., 2010). We also observed this 
pattern of myelin loss in our samples, but it was much less prominent 
than the more diffuse changes in myelin structure (increased fragmen-
tation, tortuosity, and bead-like varicosities) which we report here. To 
our knowledge, these findings have not been reported before in human 
Alzheimer’s disease, but strikingly similar myelin alterations were recently 
discovered in a mouse model of Alzheimer’s disease (Chen et al., 2011).
Apart from its role in myelin metabolism, iron is an important upstream 
and downstream modulator of several molecular pathways in Alzheim-
er’s disease. Recently it was demonstrated that APP plays a physiological 
role in preventing iron-mediated oxidative stress in the brain (Duce et 
al., 2010). In Alzheimer’s disease, zinc accumulation in amyloid plaques 
and loss of soluble tau interfere with APP’s ferroxidase activity, causing 
increased neuronal iron accumulation. Furthermore, there is evidence 
that APP processing through the amyloidogenic and non-amyloidogenic 
pathways is affected by iron (Duce et al., 2010; Lei et al., 2012). Finally, 
experimental data have demonstrated that iron may accelerate Aβ oli-
gomerization (Roberts et al., 2012). Based on these observations, it has 
been suggested that iron could be an important biomarker of AD (Colling-
wood and Dobson 2006; Zhu et al., 2009).
The data presented here show convincing evidence that the cortical my-
elin cytoarchitecture and iron distribution are disturbed in Alzheimer’s 
disease patients. Although these changes might not be central to the 
pathogenesis of Alzheimer’s disease, the ability to visualize them by MRI 
creates a putative novel biomarker with the potential to reflect an as 
yet under-appreciated change that may accompany the progression of 
Alzheimer’s disease. However, our data are preliminary since they have 
been generated in a limited number of patients and healthy controls, and 
cover only a limited part of the brain. Postmortem, we observed these 
changes in SWI contrast in all patients with confirmed Alzheimer’s dis-
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ease. In vivo, we observed these changes in cortical appearance only in a 
sub-set of patients; one reason for this discrepancy may be that the pa-
tients have been included based on a clinical diagnosis (NINCDS-ADRDA 
criteria), which is known to have a limited diagnostic accuracy (77 - 85%) 
(Jobst et al., 1998). Further studies, comprising larger patient series and 
additional controls populations of patients with different types of dementia 
are required to assess the potential of the cortical changes we observed 
to constitute true diagnostic biomarkers for AD. There are many other 
important and related questions, such as whether the presence of cor-
tical changes is associated with reduced cognitive function, whether the 
changes appear early in the course of AD, and whether the frontal lobes 
are the best regions in which to detect these early changes. Additional in 
vivo and postmortem research on the correlation between ultra-high field 
MRI and pathology will allow us to further elucidate the role of iron and 
myelin in the pathogenesis of Alzheimer’s disease. Overall, the analysis 
of the cortical changes via visual inspection and simple scoring criteria, 
without the need for quantitative measurements or sophisticated image 
processing techniques, makes the proposed method very attractive as a 
diagnostic and research tool in a clinical setting.
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Abstract
Epidemiological studies indicate that the incidence of Alzheimer’s disease 
(AD) is higher in women than in men. There is evidence that changes 
in metabolites in the brain associated with the development of AD are 
present earlier than structural brain changes. The effect of sex on the 
metabolic profile during the development of AD has not yet been studied. 
In this study we longitudinally monitored and compared in vivo metabolic 
changes in male and female AβAPPswe, PSEN1dE9 transgenic mice brains 
using magnetic resonance spectroscopy. Our results show a lower level of 
glutamate as well as of N-acetylaspartate (NAA) in transgenic mice. The 
decline in NAA with age was more apparent in female mice. The level of 
taurine was higher in female mice and showed a faster decline over time. 
In conclusion, our study is the first to suggest that changes in the meta-
bolic profile during AD development are influenced by sex.
Key words:  Alzheimer’s disease; magnetic resonance spectroscopy; 
sex differences; APP/PS1 transgenic mouse model; longitudinal studies
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease that causes 
dementia and is an increasing health problem in the aging population; 
worldwide around 25 million people have AD and in 20 years this number 
will be doubled [1]. AD is associated with amyloid-β (Aβ) plaque forma-
tion, neurofibrillary tangles and cerebral cortical atrophy, mainly found in 
the hippocampus and the cerebral cortex [2]. There are strong indications 
that the clinical symptoms of AD start years after the onset of plaque 
formation [3]. Currently, AD can be diagnosed using a cognitive test com-
bined with a magnetic resonance imagining (MRI) scan of the brain to 
detect cerebral atrophy and by determining the amount of Aβ and tau 
in the cerebrospinal fluid, but not with complete accuracy [4]. Dementia 
and cerebral atrophy are very late stages of AD; therefore, drugs that 
are able to modify the disease process can only be expected to have little 
effect. If patients could be diagnosed at the onset of neurodegeneration, 
when symptoms are absent or subtle, the therapeutic window for disease 
modifying drugs would be much wider and there would be an increased 
expected gain. Therefore, a more accurate and earlier diagnosis of AD is 
of vital importance. 
It is known that females are at higher risk for developing AD than men 
[5,6]. The effect of the mentioned sex differences on the pathophysiology 
of AD has not yet been carefully examined. Hormonal influences have 
been suggested [7], however, the underlying pathways accounting for the 
sex related differences remain unknown. One way to examine the meta-
bolic pathways non-invasively during early phases of AD, and to study the 
influence of sex differences on these metabolic pathways, is by focusing 
on the metabolic changes in a transgenic(Tg) mouse model, by means 
of magnetic resonance spectroscopy (MRS). MRS is a non-invasive tool 
which can be used to measure the concentration of various brain metab-
olites in vivo [8]. Measuring these metabolic changes in vivo, using MRS, 
could help identify AD at an early stage, prior to the onset of cognitive 
symptoms [3]. Furthermore, changes in metabolic profiles could provide 
superior insight in the sex related pathophysiological mechanism of the 
disease. 
Several Tg mouse models are available that develop pathology similar, 
however, not identical to human AD. These Tg mouse models allow mon-
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Figure 1: Representative MR image and spec-
trum of the mouse brain. (A) a coronal MR 
image of the mouse brain, obtained using a 
RARE sequence, showing the position of the 
selected 22 ul (1.8x3.5x3.5 mm3) voxel cov-
ering the cortex-hippocampus region. (B) One 
dimension localized 1H-MR spectrum obtained 
from the selected 22 ul voxel placed in the 
brain of an 15 month old control mouse. Spec-
trum was obtained using a PRESS sequence 
with TR=1500 ms and TE=15 ms at 9.4T.
itoring of the metabolic changes from the onset of AD, which is not de-
tectable in patients. In the present study the AβAPPswe,PSEN1dE9 mouse 
model is used. This mouse model demonstrates many of the cognitive 
[9] and neuropathological features of human AD, including plaque de-
velopment. These mice develop plaques at 6 months of age and show 
decreased performance of exploratory activity and spatial learning tests 
at 12 months of age [9]. In reproductive phenotype no differences are 
found between this mouse model and control mice. Studies using this 
mouse model have mainly focused on histological data, including staining 
for Aβ, iron, and glial cells [10-16]. Among these histological studies, no 
sex-related differences were reported. However, in other AD mouse mod-
els, a sex-related difference was found, showing more Aβ in female mice 
[17,18]. For glial cells no sex difference was found yet.  
Numerous MRS studies have been performed using Tg mouse models 
of AD. However, until now, the effect of sex on AD related metabolic 
changes has not been studied. The results of previous MRS studies have 
shown AD-related abnormalities for several metabolites [11,16,19-25]. 
N-acetylaspartate (NAA) in the brain is present predominantly in neuronal 
cell bodies. Decreased NAA levels, indicating neuronal damage, have been 
found in Tg mice in comparison to wild type (wt) mice [11,20-24]. Myo 
inositol (mIns) and taurine play a role in osmoregulation and are mainly 
found in astrocytes of brain tissue. These metabolites were found to be 
higher in Tg mice than in wt mice [11,19-22]. Glutamate (glu) is an excit-
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atory neurotransmitter, involved in learning, memory forming, and cog-
nition, which is found to be decreased in mice with AD [20-25]. Whether 
the changes in these metabolites during AD progression are sex specific, 
and whether they correlate temporally with timing of plaque deposition in 
male and female mice, remained to be investigated. 
In this paper, we present the first systematic longitudinal MRS study to 
investigate the sex-related differences in metabolic changes during de-
velopment of AD in the AβAPPswe,PSEN1dE9 mouse model. The main 
findings of this study were the differences between male and female mice 
in NAA, taurine, and histological data. These results suggest that changes 
in the metabolic profile during AD development are clearly influenced by 
sex. Based on this, future MRS studies should consider specifying sex of 




In this study 20 AβAPP/PS1 transgenic mice (12 male, 8 female); B6C3-
Tg (AβAPPswe,PSEN1dE9) 85Dbo/Jtg/0 from the Jackson Laboratory (Bar 
Harbor, ME, USA) and 20 wildtype (wt) littermates (7 male, 13 female) 
were used. 10 Tg mice and 10 wt mice were followed for 18 months and 
scanned every 3 months (timepoints: 3, 6, 9, 12, 15 and 18 months). For 
each timepoint, following MRI, 2 Tg and 2 wt mice of the remaining 10 
Tg and 10 wt mice were sacrificed for histological analysis; at timepoint 
18 months the mice used for the longitudinal study were sacrificed. The 
Institutional Animal Care and Animal Use Committee approved all the ex-
periments in accordance with the NIH guide for the care and use of Labo-
ratory animals. The mice were kept in a 12 hour light/dark circle. 
Magnetic resonance spectroscopy
All  measurements  were  conducted at 25°C on a vertical wide-bore 9.4T 
Bruker Avance 400WB spectrometer, with a 1000 mTm-1 actively shielded 
imaging gradient insert (Bruker BioSpin, Ettlingen, Germany). The RF coil 
used was a 25 mm volume RF coil, specifically, a birdcage transmit/re-
ceive coil (Bruker BioSpin). The system was interfaced to a Linux pc run-
ning Topspin 2.0 and Paravision 5.0 imaging software (Bruker BioSpin). 
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Mice were anaesthetized for in vivo MRS measurements using isoflurane 
(Forene, Abott, UK), inhalation anaesthesia, in addition with air and oxy-
gen (1:1) at 0.2 litre/minute. The anaesthetic gas was administered via 
a special facemask, which also served as a fixation device for the mouse 
head since it was coupled to a specially designed toothbar to hold the 
head in place (Bruker Biospin GmbH). The respiration rate of the mouse 
inside the probe was constantly monitored using a pressure transducer 
placed on the abdomen. The transducer was connected to a BioTrig ac-
quisition module, which was interfaced to a BioTrig command module and 
laptop running BioTrig BT1 monitoring software (Bruker Biospin GmbH).
Localized T2-weighted multislice RARE images were acquired to select a 
volume of interest [25]. The MRS voxels were localized in the cortex-hip-
pocampus regions in the mouse brain (1.8x3.5x3.5 mm3; 22 µl) (fig. 
1). The localized homogeneity was optimized by adjustment of first- and 
second-order shim coil currents using the FASTMAP sequence [26]. The 
field homogeneity in a 22 µl voxel typically resulted in water line-widths 
of 20-25 Hz. 
The PRESS (Point Resolved Spectroscopy) sequence [27] was used for 1D 
localized 1H MR spectroscopy. This sequence uses 3 hermite RF pulses 
(90°, 180°, and 180°). The sequence details are described by Mandal 
et al., 2007. The repetition time and echo time were 1500 ms and 15 
ms, respectively. The PRESS sequence used 2048 complex points, with a 
spectral width of 10 ppm. The final 1D spectra were obtained with num-
ber of scans of 256 and scan times of approximately 15 minutes. The 1D 
PRESS sequences were preceded by a VAPOR sequence [28] for global 
water suppression. The sequence consists of 7 variable power RF pulses 
with an optimized relaxation delay. The relaxation delays τ1-τ7¬ between 
the consecutive pulses were 150, 80, 160, 80, 100, 37.11 and 57.36 ms. 
Water suppression bandwidth was set at 350 Hz. Outer volume suppres-
sion (OVS) was combined in an interleaved mode with a water suppres-
sion scheme. This improves the localization performance and reduces the 
demands for spoiler gradients. The OVS scheme used a total of 18 hyper-
bolic secant RF pulses, each with 90° nominal flip angle and 1 ms pulse 
length. The OVS slice thickness was 4 mm with a 0 mm gap to the voxel. 
The acquired in vivo 1D MR spectra were analyzed using LCModel [29]. 
This calculates the best fit of the experimental spectrum based on a linear 
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Figure 2: Longitudinal monitoring of sex related differences in (A) glutamate (glu)/Cr ra-
tio, (B) NAA/Cr ratio (C) Tau/Cr ratio and (D) mIns/Cr ratio in the cortex-hippocampus 
regions of all mice, male and female mouse brain measured using in vivo MRS at 9.4 T.
combination of model spectra. The final analysis was performed in the fre-
quency domain; however, raw data (FIDS) was used as standard data in-
put. The following metabolites were included in the basis set for LCModel: 
alanine (Ala), aspartate (Asp), creatine (Cr), γ-aminobutyric acid (GABA), 
glucose (Glc), glutamate (Glu), glutamine (Gln), glycerophosphocholine 
(GPC), choline (cho), phosphocholine (PCho), myo-inositol (Ins), lactate 
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Table 1: R2 of the linear regression line of the metabol-
ic changes over time in wild type (wt) and transgenic (tg) mice. The differenc-
es are shown in male (M) and female (F) for glutamate, NAA, taurine and myo inositol.
(Lac), N-acetylacetate (NAA), N-acetylaspartylglutamate (NAAG), phos-
phocreatine (PCr), phosphoethanolamine (PE), scyllo-inositol (sIns), and 
taurine. Quantification was obtained using the tCr resonance as an in-
ternal standard, in our study no difference was found in creatine. The 
LCModel fitting was performed over the spectral range from 0.2 to 4.2 
ppm. Signal to Noise ratio was above 5 and a %SD of 20 or lower.
Histology
Following in vivo MRS measurements, 2 wt and 2 Tg mice were sacrificed 
at each timepoint, and their brains were fixed in 4% buffered formalde-
hyde. Following fixation, the brain was dehydrated and embedded in par-
affin, after which coronal sections (8 µm thick) were carefully cut using a 
microtome. To detect the Aβ plaques, brain sections were pretreated for 
1 hour with 70% formic acid followed by treatment with trypsin for 30 
min at 37°C. Subsequently sections were washed in PBS and subjected to 
immunohistochemistry using the primary antibody polyclonal anti-amy-
loid-beta 40-42 antibody at 1:1000 (Alpha Diagnostics International, San 
Antonio, USA) overnight followed by a secondary antibody swine anti-rab-
bit (Dako) 1:600 for 1 hour. After washing 3 times with PBS immunola-
belling was followed using a ABC kit (Vectastain) according to the man-
ufacturer’s instructions and visualized with DAB (3,3’ diaminobenzidine, 
Sigma). Detection of iron was done by a DAB-enhanced Perl’s staining 
according to Smith et al. [30]. To stain glial cells, a primary polyclonal an-
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Table 2: Mean ratio of glu, NAA, taurine and mIns with respect to Cr in 3 and 18 
months old wild type (wt) and transgenic (tg) mice (mean + standard deviation). Wt 
and tg were separated in male (M) and female (F). *difference between male and fe-
male mice at 18 months for glutamate was significant (p < 0.05) for both wt and tg. 
ti-GFAP (glial fibrillary acidic protein) antibody (Dako) was used following 
standard procedure. To detect the activated microglia and macrophages a 
primary polyclonal anti-IBA1 (ionized calcium binding adaptor molecule 1) 
antibody 1:1000 (Wako Chemicals, Neuss, Germany) was used. Prior to 
the IBA-1 antibody, a pretreatment with trypsin was performed for 30 min 
at 37ºC. Since the plaque development in APPswe, PSEN1dE9 transgenic 
mouse starts at approximately 6 months of age, the histological data in 
male and female mice are shown at the age of 3, 6 and 9 months. 
Histological images were acquired using a panoramic midi scanner (3D 
Histech, Budapest, Hungary). For quantitative histological analysis, re-
gions of interest (ROIs) were selected in the cortex and hippocampus 
and the area percentage of stained tissue was calculated in these ROIs 
using ImageJ software (ImageJ, USA). The colours were unmixed using 
the plug-in colour deconvolution, the stained area was selected and the 
percentage of the total area was calculated using analyzing particles.
Statistical analysis
To investigate significant age-related differences between either sex or 
Tg and wt, a mixed model analysis was performed including scatter plots 
using SPSS software (version 17.0; SPSS, Inc., Chicago, IL). Mean differ-
ences were compared using one way ANOVA with statistical differences of 
p<0.05 stated as significant.
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Figure 3: Quantitative analysis of sex related differences in Aβ (A) and iron (B) deposition 
in wt and tg mouse brain. (a) Surface percentage (%) of deposition in the cortex of wt and 
tg mice; (b) % of deposition in the cortex of male and female tg mice; (c) % of deposition 
in the hippocampus of wt and tg mice; (d) % of deposition in the hippocampus in male 
and female tg mice. Percentage of Aβ and iron deposition in the cortex and hippocampus 
elevate during the development of AD in tg mice. The elevations starts earlier in female 
mice as compared to male mice. 
Results
Magnetic resonance spectroscopy
Of all metabolites measured only glu, NAA, tau and mIns are presented 
because they show either statistical significant results or a trend.
As shown in figure 2A, the glutamate (glu)/Cr ratio was lower in Tg mice 
compared to wt mice at all ages (Fig. 2A; table 1 and 2), and the rate of 
decline in glu/Cr ratio with age was more pronounced in Tg mice than in wt 
mice. A sex difference in the level and rate of decline in glutamate became 
apparent after separation of the data of male and female mice. In male 
wt mice, the glu/Cr ratio decreased over time, in contrast to wt female 
mice, in which it slightly increased. However, in Tg mice the glu/Cr ratio 
decreased in both male and female. At 18 months a significant difference 
(p < 0.05) is found between wt male (0.84) and wt female (0.97) mice, 
and between Tg male (0.87) and Tg female (0.94) mice (table 1 and 2). 
The NAA/Cr ratio was higher in wt mice in comparison to Tg mice (Fig. 
2B; table 1 and 2) and decreased over time in both wt and in Tg mice. 
Overall the NAA/Cr ratio was higher in female when compared to male in 
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Figure 4: Aβ staining (A), GFAP staining (B) and IBA-1 staining (C) in brain sections of 6 
months (6 mo) and 9 months (9 mo) old transgenic (tg) male and tg female mouse. Magni-
fied area of (1) cortex (scale bar 200 um) and (2) hippocampus (scale bar 500 um) is shown. 
Arrows indicated immune stained Aβ plaques, GFAP depositions and IBA-1 depositions.
both wt and Tg mice. In female mice a faster decrease in NAA/Cr ratio was 
observed in Tg than in wt mice leading to a more apparent difference at 
18 months of age than in males. Female Tg mice showed a faster decline 
than male tg mice (Fig. 2B (b,c)).
When male and female mice were taken together the ratio of taurine/Cr 
was similar for Tg and wt mice at all time points (Fig. 2D; table 1 and 2). 
Male wt and Tg mice showed a comparable taurine/Cr ratio at 3 months 
and a similar decrease over time. Female Tg mice showed a much strong-
er decline compared with male Tg and female wt mice. The taurine/Cr 
ratio in female Tg mice started higher at 3 months and ended lower at 18 
months than in male Tg, female wt and male wt mice.
  
In Tg mice the mIns/Cr ratio started lower than in the wt mice and in-
creased over time while this ratio slightly decreased in wt mice (Fig. 2C; 
table 1 and 2). Separating male and female mice showed comparable 
results.
Histology
Figure 4 shows the results of Aβ in the brain sections of 6 and 9 month 
old male Tg and female Tg mice. The Aβ deposition in the brain increased 
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more rapidly in Tg female mice than in Tg male mice (Fig 4A). Iron depo-
sition showed the same pattern as Aβ deposition. No Aβ or iron deposition 
was found in wt mice, even at 9 months.  
This difference between male and female was more prominent in the cor-
tex than in the hippocampus (fig 3 and 4).
Quantification of the amount of GFAP and IBA-1 showed no difference 
between wt and Tg mice. However, in the Tg mouse brain the distribution 
of both GFAP and IBA-1 became irregular over time, because GFAP and 
IBA-1 positive cells aggregate around plaques (Fig. 4B, C). In wt mice the 
deposition of GFAP and IBA-1 was more evenly distributed than in Tg mice 
(Fig. 4B,C). The presence of these plaque associated GFAP depositions 
was visible earlier in female brain than in male brain (Fig. 4B). 
 
Discussion
This is the first longitudinal study showing that changes in metabolic pro-
file during AD development are influenced by sex in a mouse model of 
AD. The main findings of this study are: (1) female mice have increased 
plaque development as well as increased activation of microglia surround-
ing the plaques compared with male mice, and (2) the decline in NAA and 
taurine during AD development is more apparent in female Tg mice than 
in male Tg mice in both the cortex and hippocampus. Most of these dif-
ferences are statistically not significant, probably due to the low number 
of mice and lower inter individual variability at the different time points, 
but a trend is apparent. We tried to limit inter individual variability by 
scanning the wt and Tg mice for each time point at the same day with the 
same protocol. Instrumental limitations were excluded as far as possible 
by doing phantom studies, being preparations with known amounts of 
metabolites.
One lesson we learned from our study is that sex-specific differences be-
tween animals can influence study results. Comparison of wt and Tg mice 
show different results than comparison of the individual male and female 
subpopulation. For instance, the difference in NAA/Cr ratio between fe-
male wt and Tg mice increases over time, while for male Tg and wt mice 
the difference in NAA/Cr ratio decreases. This may explain why the re-
sults, as presented in our study, differ at some parameters from earlier 
studies [11,22,23,25]. 
We observed an increase of the glu/Cr ratio in female wt mice and a de-
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crease in male wt mice over time, which indicates that the glu/Cr ratio 
between wt and Tg is sex dependent. In several earlier studies glu/Cr 
ratio changes were observed, but the sex of the studied mice was not 
mentioned or sex was not taken into account in the analysis of the data 
[11,21,22,24]. 
In a previous study [22], mIns was increased in Tg mice compared with 
wt mice, however male and female mice in the Tg group were presented 
together, while only female wt mice were used, which means the 2 groups 
could in fact not be compared due to the sex differences. Chen et al. [11] 
found no significant differences between male and female and this study 
confirmed the differences between Tg and wt mice found by Marjanska et 
al. [22]
The ratio of taurine/Cr was higher in female Tg mice than in wt mice at 
an early age (3 and 6 month), but at 9 months the taurine/Cr ratio was 
lower in female Tg mice. However, the mIns/Cr ratio started slightly lower 
in the Tg mice than in the wt mice (3 and 6 months), but, at 12 month 
the ratio of mIns/Cr was higher in the Tg mice than in the wt mice. Myo 
inositol and taurine are known to be involved in osmotic regulation across 
the cellular membrane and are mostly present in glial cells [22]. Despite 
these functional similarities our results indicate that in tg mice the two 
metabolites show an opposite trend; mIns slightly increases with age (as 
opposed to a stable amount in wt) and taurine decreases with age (more 
than the decrease in wt).
Our histological data show an increase in plaque deposition in Tg mice 
which was correlated with an increase in iron as well as an increase of 
GFAP positive glial cells around plaques with age. This increase was more 
apparent in the female mice. Previous histological studies in AβAPP/PS1 
mice have shown an increase in plaque deposition after 3 to 5 months. In 
addition, an increase in GFAP positive glial cells is reported in these mice 
at 5-8 months [11,14,15,31]. However, these studies did not show sex 
differences in deposition of plaque, iron or GFAP. 
Although the pattern of GFAP positive cells changes while plaques devel-
op in the brain, the overall density of these cells is not clearly different 
between wt and Tg brain tissue. This is reflected by the minimal increase 
of myo inositol and even a decrease of taurine, both osmoregulatory pro-
teins, which are particularly present in glial cells.
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The increased level of the NAA/Cr ratio in the female brain, for both wt 
and Tg mice, can be explained by the fact that females seem to have a 
higher cerebral axonal density than males [32]. The mechanisms respon-
sible for the sex differences in Aβ and iron deposition are not yet known.
Our study is the first study to systematically investigate the influence of 
sex on metabolic and histological changes in AD over time using an AD 
mouse model. The use of a mouse model allows examining early changes 
in AD, which is not possible in humans. Our findings show for the first time 
that changes in metabolic profile during AD development is influenced by 
sex. These results are in line with the known higher risk of AD in women 
[5,6]. The area of sex differences in AD is still largely unexplored but 
knowledge of metabolic differences would offer great promise for diagno-
sis and for the future development of better strategies for intervention in 
patients.
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Summary and general discussion
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Summary
The central theme of this thesis is to study the possibilities of an early 
diagnosis of Alzheimer’s disease (AD) using different MR techniques with 
pathological confirmation. 
The current view on AD is that neuropathological changes start two dec-
ades before the occurrence of clinical symptoms (Jack, Jr. et al., 2010). 
The cognitive decline associated with AD represents a late stage of the dis-
ease when neurodegeneration is extensive and therapeutic interventions 
may be too late. In the coming years, the radiological changes associated 
with AD need to be validated and expanded to allow diagnosis in vivo, 
perhaps even at an early stage of the disease. The search for new imaging 
methods is driven by the promise that earlier diagnosis, preferably before 
obvious dementia is present, may help in the search for treatment and to 
identify patients early enough to benefit from future treatment.
In the study discussed in chapter 2 the findings of coarse hypointensities 
on postmortem brain MRI were examined, correlated with pathology and 
discussed. During experiments with ex vivo human brain material, large 
hypointensities were visible on MRI scans. These turned out to be tissue 
artifacts induced by prolonged formalin storage without refreshing the 
formalin. This chapter describes the usability and limitations of postmor-
tem brain tissue for MRI. Postmortem brain tissue is often used for MRI 
and pathological research (Benveniste et al., 1999; Bobinski et al., 2000; 
Bronge et al., 2002; Englund et al., 2004; Fernando et al., 2004; Geurts 
et al., 2005; Gouw et al., 2008; House et al., 2007; Kangarlu et al., 2007; 
Larsson et al., 2004; Schmierer et al., 2010; van Rooden et al., 2009) but 
there are limitations. Fixed brain tissue stored in unrefreshed formalin for 
prolonged periods (longer than a year), shows structural tissue changes 
associated with hypointensities on MR images. The fixation protocol for 
prolonged storage of tissue without refreshment of the formalin may be 
common practice in brain banks. Researchers should be aware of this fix-
ation artifact. 
Iron
For many years, research has been focusing on Aβ accumulation in 
plaques and the intraneuronal accumulation of hyperfosforylated of tau, 
as these are the pathological hallmarks of AD (Nelson et al., 2009). The 
last decade, increasing evidence suggests the importance of iron in the 
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pathogenesis of AD (Bartzokis, 2011; Crichton et al., 2002; Haacke et al., 
2005; Meadowcroft et al., 2009; Meadowcroft et al., 2015a; Nabuurs et 
al., 2011). Iron is present in plaques and microglia, which may serve as 
an early marker for AD. To demonstrate iron, various histological staining 
methods have been developed (LeVine, 1991; Meguro et al., 2007; Smith 
et al., 1997). In chapter 3 we describe the comparison of three histolog-
ical iron staining methods and ferritin immunohistochemistry to visualize 
iron in paraffin-embedded human AD brain tissue. The specificity of the 
histochemical techniques was tested by staining sections after iron ex-
traction. Iron was demonstrated in the white matter, in cortical layers IV 
and V of the frontal neocortex, in iron positive plaques and in microglia. 
In our hands, these structures were best visualized using the Meguro iron 
staining method (Meguro et al., 2007), a method that has not yet been 
described for iron staining in human brain or AD.
Chapter 4 discusses the iron changes in the frontal cortex of AD brains 
compared to control brains. The aim of this study was to assess the histo-
logical distribution of iron in aging and in AD. The frontal cortex with AD 
pathology showed iron accumulation in plaques and activated microglia. 
This is in line with earlier studies showing iron in human Aβ plaques (LeV-
ine, 1997; Nabuurs et al., 2011; Nabuurs et al., 2013; Smith et al., 1997) 
and in activated microglia (Connor et al., 1992; LeVine, 1997; Nabuurs 
et al., 2011; Nabuurs et al., 2013). In addition to iron in plaques and mi-
croglia in AD cortex, we confirmed our preliminary observation (van Duijn 
et al., 2013) of an increased labelling of iron and myelin protein along 
myelinated fibres in and around cortical layers IV/V in a subset of AD 
patients with the most severe tau pathology. This is in line with the close 
relationship between iron and myelin synthesis extensively described in 
the literature. For example, activated microglia have been described to 
drive the recruitment and proliferation of oligodendrocyte proliferating 
cells (OPC) and their differentiation to oligodendrocytes, as well as the 
formation of myelin sheath around available axons (Crawford et al., 2013; 
Gudi et al., 2014; Miron and Franklin, 2014). Moreover, it is thought that 
microglia provide the high iron concentrations needed for myelinization 
and oligodendrocyte differentiation (Schonberg et al., 2012; Schonberg 
and McTigue, 2009; Todorich et al., 2009).
We observed that aging in the absence of Aβ plaques does not lead to 
changes in iron distribution. Finally, we showed a semi-quantitative as-
sociation between iron accumulation and the stage of AD pathology. This 
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opens the possibility to grade the severity of AD pathology by MR in vivo. 
Figure 1 shows iron aggregations correlated with other histological chang-
es during the development of AD. Plaque load does not increase much 
from Braak IV to VI stages but iron accumulation and tau pathology both 
progress, although we still do not understand how they are related.  
Figure 1:Schematic representation of the relation between AD pathology and patholog-
ic Fe accumulation in frontal cortex. a: normal aging showing diffuse myelin associated 
iron in the lines of Baillarger; b: controls with few diffuse plaques without pathological 
Fe accumulation; c: controls with little diffuse plaques and minimal pathological iron ac-
cumulation; d: controls with increasing plaques, including classical plaques and minimal 
AT8+ neuropil threads (AT8+NT) with increasing Fe accumulation in plaques and acti-
vated microglia; e: AD with maximum Aβ plaques and diffuse increase of AT8+NT with 
increased iron in plaques and activated microglia; f: AD with similar Aβ plaques and in-
creased AT8+NT, macroscopically visible on the slide in cortical layer V and increased iron 
in plaques and activated microglia; g: AD with similar Aβ plaques and increased AT8+NT, 
macroscopically visible in cortical layer V and other layers; h: Same severe AD pathology 
as in g but with diffuse myelin associated increase of Fe in and around cortical layer IV/V
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Magnetic Resonance Imaging
The clinical diagnosis of AD is based on neuropsychological testing com-
bined with hippocampal atrophy assessed by magnetic resonance imaging 
(MRI) and Aβ and tau levels in CSF (Fox et al., 1996; Hyman et al., 2012; 
Jack, Jr. et al., 2010; Li and Wahlund, 2011; Nasrallah and Wolk, 2014).
Over   the   past   few   years,   the   feasibility   to   detect      the     his-
tological  hallmarks   of AD using MRI has been explored; in general these 
efforts have focused on detecting individual amyloid plaques (Chamber-
lain et al., 2011; Wadghiri et al., 2013). Increased iron accumulation in 
amyloid plaques induces a magnetic susceptibility effect, visible as hy-
pointense foci on T2*-weighted or susceptibility-weighted (SW) MRI in 
the cerebral cortex of transgenic AD mouse models and in human post-
mortem brain slices (Chamberlain et al., 2011; Meadowcroft et al., 2009; 
van Rooden et al., 2009). These findings have not yet been convincingly 
replicated in vivo in patients. It is doubtful whether detecting individual 
amyloid plaques with MRI will be possible in a clinical setting given the 
required high resolution, limited scanning time and physiological move-
ment of the patient. However, recent advances in human MRI systems 
operating at an ultra-high magnetic field strength (7 Tesla and higher) 
show that the increased sensitivity to susceptibility effects generates iron 
based contrasts in the human brain that have not been observed before 
(Fukunaga et al., 2010; Meadowcroft et al., 2015b). 
Previous studies showed band like changes (van Rooden et al., 2009) and 
single plaques (Chamberlain et al., 2011; Meadowcroft et al., 2009) in the 
frontal cortex of AD patients and not in non-demented controls. These 
studies suggested effects of the amyloid plaques on the MR images. In 
chapter 5 we examined changes in cortical appearance of AD patients us-
ing susceptibility weighted 7T MRI and correlated these findings with ex 
vivo scans and pathology. The aim of this study was to establish wheth-
er 7T MRI allows in vivo detection of differences in the cerebral cortex 
between probable AD patients and healthy controls. Having observed a 
difference, we then determined the histological substrate of the changes 
by comparing MRI, light- and electron microscopic analyses on human 
post-mortem material of AD patients and controls. On MRI, diffuse hy-
pointens bands were frequently found in the cortex of the frontal lobe 
of AD patients (57%), which were not observed in healthy age matched 
control subjects. Further histologic correlation revealed that the pattern 
of the susceptibility-weighted contrast in the cortex of AD patients did not 
primarily co-localize with amyloid plaques or neurofibrillary tangles, but 
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with myelin-associated iron accumulation and with an altered myelin cy-
toarchitecture. This band like pattern of iron/myelin in the neuropil fibres 
of cortical layers III-V appears to be accentuated by the iron accumulation 
in Aβ plaques found more frequently in layer III of the cortex, confirming 
the findings in chapter 4. Iron is, due to its magnetic characteristics, easy 
to see on an MRI (Fjell and Walhovd, 2012; Karran et al., 2011). The cur-
rent findings show great promise for the in vivo detection of the underly-
ing pathological changes in AD. 
To verify our results in the frontal cortex, described in chapter 5, a larger 
set of ex vivo brain material of different brain locations should be studied. 
Another study should include comparison of AD patients to other neuro-
degenerative diseases and control subjects. The study described in chap-
ter 5, suggests that MRI changes can be observed only in a late stage in 
AD. This has potential use to follow treatment and to improve the clinical 
diagnosis at a late stage, however is not useful for early diagnosis 
Magnetic Resonance Spectroscopy 
One way to examine the metabolic pathways non-invasively during the 
early phases of AD is by focusing on the metabolic changes in a transgenic 
(tg) mouse model, by means of magnetic resonance spectroscopy (MRS). 
MRS is a non-invasive tool which can be used to measure the concentra-
tion of various brain metabolites in vivo (Rupsingh et al., 2011), making 
it possible to follow family members of AD patients with the possibility to 
identify AD at an early stage, prior to the onset of cognitive symptoms 
(Jack 2010). 
Numerous MRS studies have been performed using tg AD mice. Until now 
N-acetylaspertate (NAA) and glutamate (glu) have been found to decrease 
in tg mice compared to control mice (Braakman et al., 2008; Choi et al., 
2010; Dedeoglu et al., 2004; Marjanska et al., 2005; Oberg et al., 2008; 
von Kienlin M. et al., 2005). NAA is found in neuronal cell bodies and is 
a source of myelin synthesis in oligodendrocytes, the glial cells that my-
elinated neuronal axons. A decrease in NAA indicates neuronal damage. 
Glu is a neurotransmitter involved in memory formation and learning; 
decrease of glu indicates less neuronal activity. Myo-inositol (mIns) and 
taurine (tau) are involved in osmoregulation and are found in astrocytes, 
indicating an immune response; both increase during the development of 
AD in tg mouse compared to wt mice (Chen et al., 2009; Choi et al., 2010; 
Dedeoglu et al., 2004; Marjanska et al., 2005; Westman et al., 2009).
Chapter 6 describes the findings in the first longitudinal MRS study on a 
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transgenic mouse model. This study showed decreased glu and NAA in 
tg mice compared to wt mice at all time points. There was a decrease in 
mIns found in tg mice compared to wt mice at 3 months. Over time this 
decrease became less and at 18 months there was no difference between 
tg and wt mice in the level of mIns. At 3 months the level of tau was in-
creased in tg mice compared to wt mice, this difference disappeared over 
time and at 18 months there was no difference in tau levels between tg 
and wt mice. Our findings confirm earlier findings in studies on transgenic 
mice (Braakman et al., 2008; Chen et al., 2009; Dedeoglu et al., 2004; Li 
and Wahlund, 2011; Marjanska et al., 2005; Oberg et al., 2008; Rupsingh 
et al., 2011; von Kienlin M. et al., 2005; Westman et al., 2009; Xu et al., 
2010). These differences were not significant, probably due to the small 
size of the study group. 
Currently, the long acquisition times limit the use of MRS in AD patients. 
If technical improvements are successful, the obvious next step would be 
to study large test groups of AD patients over time and compare those to 
non-demented subjects and, in a later stage, to patients with other neu-
rodegenerative diseases.
Another finding, described in chapter 6 is a sex difference in AD mice 
and wt mice using MRS. It is known that females are at higher risk for 
developing AD than men (Andersen et al., 1999; Kim et al., 2015; Mu-
sicco, 2009). In this study female mice started with increased levels of 
NAA, compared to male mice, in both tg and wt mice. Female mice have 
a larger axonal density compared to male, which might explain the higher 
levels of NAA in both female control and tg mice at 3 months of age. The 
decline of NAA in tg female mice was more precipitous compared to con-
trol mice. The difference in glu levels between male and female wt mice 
at 18 months was a significant one. Female wt mice showed higher levels 
of glu compared to male wt mice. The level of taurine was higher in tg 
female mice compared to tg male mice at 3 months and showed a faster 
decline over time. 
The effect of sex on the pathophysiology of AD has not yet been carefully 
examined. Hormonal influences have been suggested, however more re-
search is necessary (Janicki and Schupf, 2010). It will be of great interest 
to study sex differences between AD and control groups in animals or in a 
non-invasive way in human subjects. 
Our study is the first to show that metabolic changes during AD devel-
opment are influenced by sex differences. This study is done in a small 




This thesis aimed to improve the clinical diagnosis of AD by using native 
contrast MRI and MRS. MRI was correlated to histology with a special fo-
cus on iron because iron has high magnetic susceptibility effects on MRI 
and some reports show iron accumulation in Aβ plaques (LeVine, 1997; 
Nabuurs et al., 2011; Nabuurs et al., 2013; Smith et al., 1997) as well as 
in activated microglia (Connor et al., 1992; LeVine, 1997; Nabuurs et al., 
2011; Nabuurs et al., 2013) and myelin (van Duijn et al., 2013). 
We found changes in neocortical layers III-V, seen as band like hypoin-
tensities, on MRI scans which were correlated to a histological band-like 
pattern of iron/myelin in the neuropil fibres of cortical layers III-V. This 
band reflects a more crowded network of neuropil fibres with thicker and 
darker staining for iron. Iron was found in plaques, microglia and myelin 
in the neuropil. We also found a correlation between iron and neurofibril-
lar degeneration and plaques.
These MRI changes were observed only in a later stage of AD but may 
improve clinical diagnosis and enable monitoring effect of future experi-
mental treatments.
The MRS studies  showed early changes in metabolic levels between con-
trol mice and AD mice and between male and female mice. 
Our results on MRI and MRS have potential  to improve the clinical diagno-
sis of AD, however, more research is necessary.  Follow up studies should 
be done in human test groups using MRI and MRS to confirm our findings 
that a hypointense band on MRI and metabolic changes predict AD. These 
studies should focus on a large group of direct family members of early 
AD patients, who are at risk for AD and  compare these to a control group. 
These groups should be followed over time, doing MRI scans to check for 
the myelin/iron band and MRS scans to check for metabolic changes with 
caution for sex differences. Another study should focus on the specificity 
of the band like changes found on MRI scans. These band like hypointen-
sities might not be specific for AD, which makes it necessary to compare 
AD patients also to other neurodegenerative diseases. 
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De ziekte van Alzheimer (AD) is de meest voorkomende vorm van de-
mentie met veroudering als belangrijkste risicofactor. De toenemende 
vergrijzing gaat dan ook gepaard met een stijgende incidentie van AD 
en drukt hierbij een zwaar stempel op de maatschappij, zowel op so-
ciaal-economisch als op medisch vlak. De precieze oorzaak van deze 
ziekte is echter onbekend en helaas ontbreekt tot nu toe een behandeling.
AD wordt veroorzaakt door de ophoping van twee verschillende eiwitten 
in de cortex van de hersenen. Het meest bekende eiwit is het amyloid-β 
(Aβ) peptide hetgeen amyloid plaques vormt. Het tweede eiwit is gehy-
perfosforyleerd tau in de vorm van neurofibrillaire tangles. De ophoping 
van beide eiwitten lijkt vroeg te beginnen, tientallen jaren voor de eerste 
klinische symptomen zichtbaar worden. Detectie van deze accumulatie in 
vivo in een vroeg stadium is vooralsnog  niet mogelijk. Op dit moment is 
een definitieve diagnose van AD alleen postmortem te stellen.
Een vroege diagnose zou het mogelijk maken de ontwikkeling van de 
ziekte te volgen en het begrip van het verloop van AD te vergroten. Hier-
door zou  behandeling weer een stap dichterbij zijn. In dit proefschrift heb 
ik mij gericht op verschillende technieken die een vroege diagnose mo-
gelijk zouden kunnen maken, namelijk magnetische resonantie imaging 
(MRI) en magnetische resonantie spectroscopie (MRS) technieken. Hierbij 
heb ik mij gericht op ex vivo humaan hersenweefsel (MRI) en op muizen 
met een AD mutatie (MRI en MRS. 
Het humane hersenweefsel dat gebruikt is in deze studie is  gefixeerd in 
formaline. Bij langdurige fixatietijden bleken in het  hersenweefsel ar-
tefacten op te treden. Deze artefacten waren als hypointense gebieden 
zichtbaar op verschillende MRI-sequenties (hoofdstuk 2). Aangezien for-
maline gefixeerd postmortem hersenmateriaal vaak voor AD onderzoek 
wordt gebruikt, raden wij aan alleen met hersenweefsel te werken dat 
minder dan een jaar gefixeerd is in formaline waarbij deze formaline re-
gelmatig ververst is ter voorkoming van deze artefacten.
De rol van ijzer is in de afgelopen jaren steeds belangrijker gebleken bij 
de ontwikkeling van AD. Aangezien ijzer, door zijn magnetische karakter, 
goed zichtbaar kan worden gemaakt met behulp van MRI, lag hier onze 
focus. De histologische kleuringen die gebruikt worden om ijzer aan te to-
nen, zijn echter niet altijd specifiek en consistent. In hoofdstuk 3 wordt de 
vergelijking van verschillende histochemische kleuringen op hersenweef-
sel van AD patiënten beschreven. Uit dit onderzoek bleek dat de kleuring 
ontwikkeld door Meguro de beste techniek was voor onze doeleinden. 
Deze werd dan ook gedurende de rest van het proefschrift gebruikt.
Vervolgens werd hersenweefsel van 10 AD-patiënten vergeleken met 
het brein materiaal van 10 jonge, 10 middeloude en 10 oude controles 
(hoofdstuk 4). Dit materiaal werd getest op de aanwezigheid van ijzer 
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(met de Meguro kleuring), Aβ, myeline en tau. Uit dit onderzoek bleek dat 
ijzer bij AD-patiënten in vergevorderd stadium zich ophoopt in de lagen 
3 tot en met 5 van de cortex. Hierbij vormt het ijzer een band die goed 
zichtbaar zou kunnen zijn op een MRI-scan. Deze ijzerophoping bleek te 
zijn  gecorreleerd aan de accumulatie van tau en de verandering van het 
myelinepatroon in het AD-brein. De hoeveelheid Aβ in het brein leek hier 
los van te staan. De hoeveelheid ijzer in het brein nam pas toe nadat de 
ophoping van Aβ in de cortex al zijn maximale hoeveelheid heeft bereikt. 
In hoofdstuk 5 hebben we de veranderingen in corticale patronen van 
gezonde ouderen en AD-patiënten in vivo onderzocht met behulp van 7T 
MRI. Tegelijkertijd werden soortgelijke corticale patronen waargenomen 
bij MRI verricht op postmortem AD-hersenmateriaal. Dit materiaal bood 
tevens de mogelijkheid tot correlatie met de onderliggende pathologie ve-
rantwoordelijk voor deze signaalverandering, zoals zichtbaar op de MRI. 
In de frontale cortex van AD-patiënten was in vivo een diffuse hypointense 
corticale band zichtbaar die niet werd gezien bij gezonde controles van 
dezelfde leeftijd. Uit de histologische studie bleek dat de corticale patro-
nen op de MRI niet primair overeen kwamen met de distributie van amy-
loid plaques of neurofibrillaire tangles. Deze patronen lieten een duidelijke 
correlatie zien met microglia en myeline-geassocieerde ijzerophopingen 
evenals een veranderde corticale myeline cytoarchitectur.    
   
Deze resultaten zijn veelbelovend voor de in vivo detectie van de onder-
liggende pathologische veranderingen in AD door middel van MRI. Toe-
komstige onderzoek dient uit te wijzen of dit patroon specifiek is voor AD.
Het laatste hoofdstuk (hoofdstuk 6) beschrijft een studie, waarbij de me-
tabolietenhuishouding van muizen met AD-mutatie op verschillende mo-
menten gedurende het leven van deze muizen werd gemeten met behulp 
van de MRS. Deze bevindingen werden vergeleken met controle muizen. 
Hieruit bleek dat op vroege leeftijd, als er nog geen symptomatische ver-
schillen zijn tussen de AD-muizen en de controle muizen, al een verand-
ering in de metabolietenhuishouding zichtbaar was. Hierbij werd specifiek 
gekeken naar metabolieten die te maken hebben met schade aan neuro-
nen, die betrokken zijn bij het geheugen en metabolieten die betrokken 
zijn bij immuunreacties. Een opvallende bevinding in dit onderzoek was 
het verschil tussen mannelijke en vrouwelijke muizen. De metabolieten 
huishouding bleek bij zowel controle als AD-muizen anders te zijn in man-
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